{
  "name": "Magistra GLP-1 competitor tolerability benchmark — free sample",
  "generatedAt": "2026-10-09T05:10:30.412Z",
  "corpusAsOf": "2026-10-09T05:02:51.036Z",
  "corpusFile": "data/side-effects-db.json",
  "generator": "scripts/build-benchmark-sample.mjs",
  "minTrialsPerCell": 3,
  "effects": [
    {
      "id": "nausea",
      "name": "Nausea"
    },
    {
      "id": "vomiting",
      "name": "Vomiting"
    },
    {
      "id": "diarrhea",
      "name": "Diarrhoea"
    },
    {
      "id": "constipation",
      "name": "Constipation"
    }
  ],
  "drugs": [
    "semaglutide",
    "tirzepatide",
    "liraglutide",
    "dulaglutide",
    "exenatide",
    "lixisenatide"
  ],
  "rows": [
    {
      "key": "semaglutide_oral",
      "label": "Semaglutide (oral)",
      "drug": "semaglutide"
    },
    {
      "key": "semaglutide_injectable",
      "label": "Semaglutide (injectable)",
      "drug": "semaglutide"
    },
    {
      "key": "tirzepatide",
      "label": "Tirzepatide",
      "drug": "tirzepatide"
    },
    {
      "key": "liraglutide",
      "label": "Liraglutide",
      "drug": "liraglutide"
    },
    {
      "key": "dulaglutide",
      "label": "Dulaglutide",
      "drug": "dulaglutide"
    },
    {
      "key": "exenatide",
      "label": "Exenatide",
      "drug": "exenatide"
    },
    {
      "key": "lixisenatide",
      "label": "Lixisenatide",
      "drug": "lixisenatide"
    }
  ],
  "semaglutideUnclassified": {
    "rule": "Route read from the arm label only: 'oral' in the label, or a tablet-only dose (3, 7, 14, 25, 50 mg) -> oral; an injection-only dose (0.25, 0.5, 1, 1.7, 2, 2.4, 7.2 mg) -> injectable; a label stating neither -> unclassified, and the arm is in neither semaglutide row.",
    "oralDosesMg": [
      3,
      7,
      14,
      25,
      50
    ],
    "injectableDosesMg": [
      0.25,
      0.5,
      1,
      1.7,
      2,
      2.4,
      7.2
    ],
    "arms": 6,
    "trials": 4,
    "rateRows": 19,
    "armList": [
      {
        "nct": "NCT03574597",
        "arm": "Semaglutide",
        "nAtRisk": 8803
      },
      {
        "nct": "NCT04560998",
        "arm": "Semaglutide",
        "nAtRisk": 396
      },
      {
        "nct": "NCT05548647",
        "arm": "Behavioral Treatment + Medication (Weeks 0-60)",
        "nAtRisk": 72
      },
      {
        "nct": "NCT05548647",
        "arm": "Continued Medication (Semaglutide) (Weeks 60-72)",
        "nAtRisk": 10
      },
      {
        "nct": "NCT05891496",
        "arm": "Semaglutide Period 1",
        "nAtRisk": 11
      },
      {
        "nct": "NCT05891496",
        "arm": "Semaglutide Period 2",
        "nAtRisk": 22
      }
    ]
  },
  "method": "Registry-posted results only: ClinicalTrials.gov adverse-event tables for each drug's own trial arms, as stored in the Magistra corpus. Each cell pools the arm-level rates for one drug and one effect with the same function the site publishes its estimates with: rates from one trial collapse to one entry (the plain mean of that trial's arms), entries are weighted by sample size and extraction confidence, and the 95% interval adds a between-trial heterogeneity term on the log-odds scale. A cell with fewer than 3 distinct trials publishes no rate.",
  "caveats": [
    "statedRates counts arm-level rate rows, not independent participants: a crossover or multi-period study can post the same people in more than one arm.",
    "Registries list non-serious adverse events only above each trial's reporting threshold (usually 5%). A trial whose rate for a term fell below that threshold posts no row and is absent from the cell, which biases low-frequency cells upward.",
    "Each cell pools every dose and population its registry arms describe (obesity, type 2 diabetes and cardiovascular-outcomes trials together). Semaglutide is split into oral and injectable rows; every other drug is one row across its doses. They are not dose-matched or population-matched comparisons.",
    "obesityOnly narrows a cell to trials whose registry conditions are tagged obesity/overweight (some, such as STEP 2 and SCALE Diabetes, enrol people with type 2 diabetes as well), with the same function and the same 3-trial floor. It is printed beside the all-population figure, never instead of it.",
    "Pooling weights follow sample size, so one very large trial can carry most of a cell. Where a single trial carries more than half of a cell's pooling weight, the cell names it.",
    "Trial durations and adverse-event collection windows differ between trials; rates are as-posted, not annualised.",
    "Rates are as posted to the registry; we do not adjust them for placebo.",
    "Rates are not drug-attributed: the rule governing ClinicalTrials.gov results reporting (42 CFR 11.10) defines an adverse event as an occurrence \"temporally associated with the subject's participation in the research, whether or not considered related\" to it.",
    "Rates come from each registry's non-serious (\"Other\") adverse-event table, except for a term a trial posts only in its serious table. A participant whose event was recorded as serious is not counted in the non-serious table, and the two tables can share participants, so they cannot simply be added: every cell is a floor on all-severity incidence."
  ],
  "cells": [
    {
      "effect": "nausea",
      "effectName": "Nausea",
      "row": "semaglutide_oral",
      "rowLabel": "Semaglutide (oral)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 12,
      "ciLowPct": 1,
      "ciHighPct": 60,
      "statedRates": 23,
      "distinctTrials": 12,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 11,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 9,
        "cvot": 1,
        "obesity": 2
      },
      "dominantTrial": {
        "nct": "NCT03914326",
        "weightPct": 62.5
      },
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 2,
        "distinctTrials": 2,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 285,
              "ratePct": 19.3,
              "rowId": "33f3cd4b-bca9-419e-bd6a-9d59e92c9fbf"
            }
          ]
        },
        {
          "nct": "NCT02906930",
          "url": "https://clinicaltrials.gov/study/NCT02906930",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 175,
              "ratePct": 8,
              "rowId": "e6d31fbc-3054-4744-ab23-e6b0c98efe5d"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 175,
              "ratePct": 5.1,
              "rowId": "b38a3394-0beb-4c89-b5c5-511434d47e5b"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 175,
              "ratePct": 16,
              "rowId": "12e5508d-e98b-4d4b-86f9-f7496703680c"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 131,
              "ratePct": 5.3,
              "rowId": "e6a63de1-77e0-4cd6-9f69-9c0e851fee67"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 132,
              "ratePct": 8.3,
              "rowId": "2cf9ff21-8c98-4a23-903b-5f995bed7c3e"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 130,
              "ratePct": 9.2,
              "rowId": "2315c597-fa2f-4a1d-ba46-a4a8e5b56f36"
            }
          ]
        },
        {
          "nct": "NCT03021187",
          "url": "https://clinicaltrials.gov/study/NCT03021187",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 184,
              "ratePct": 11.4,
              "rowId": "c5720802-86c5-4428-8b0d-8bb462e17767"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 181,
              "ratePct": 16.6,
              "rowId": "def3fad0-f062-40c5-ba38-1117901d42cb"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 181,
              "ratePct": 22.7,
              "rowId": "7a70c18c-fbcd-4df5-8bf8-e1c5fe6c365b"
            }
          ]
        },
        {
          "nct": "NCT03914326",
          "url": "https://clinicaltrials.gov/study/NCT03914326",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Oral Semaglutide",
              "nAtRisk": 4825,
              "ratePct": 7.1,
              "rowId": "23198cb6-42f6-49ed-ba88-9bd2df5fe72d"
            }
          ]
        },
        {
          "nct": "NCT04109547",
          "url": "https://clinicaltrials.gov/study/NCT04109547",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 130,
              "ratePct": 4.6,
              "rowId": "b44d6572-e1c2-4081-acf2-3e7706c2fd06"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 130,
              "ratePct": 3.1,
              "rowId": "79c77b47-5f64-4ed0-90e7-542d3998488e"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 129,
              "ratePct": 6.2,
              "rowId": "0e334574-4de7-4d82-bdc2-ca59518714ec"
            }
          ]
        },
        {
          "nct": "NCT04596631",
          "url": "https://clinicaltrials.gov/study/NCT04596631",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide",
              "nAtRisk": 66,
              "ratePct": 25.8,
              "rowId": "1097c759-c2ea-49ec-833f-a1f65cd781b2"
            }
          ]
        },
        {
          "nct": "NCT04707469",
          "url": "https://clinicaltrials.gov/study/NCT04707469",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 534,
              "ratePct": 18,
              "rowId": "6d3a506f-1a01-4c10-816d-3c851b41db8c"
            },
            {
              "arm": "Oral Semaglutide 25 mg",
              "nAtRisk": 534,
              "ratePct": 27.2,
              "rowId": "404ff4b8-4153-48a0-930f-9a6c06ef6071"
            },
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 534,
              "ratePct": 27.3,
              "rowId": "2b721aa8-a5e0-46ae-b7b7-19d47bc3982d"
            }
          ]
        },
        {
          "nct": "NCT05035082",
          "url": "https://clinicaltrials.gov/study/NCT05035082",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide",
              "nAtRisk": 500,
              "ratePct": 7.6,
              "rowId": "d08f9820-5c17-43ad-9e33-21a8287c8b4e"
            }
          ]
        },
        {
          "nct": "NCT05035095",
          "url": "https://clinicaltrials.gov/study/NCT05035095",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 334,
              "ratePct": 51.8,
              "rowId": "74301fae-2eff-4fc2-9f2d-805f674a9b12"
            }
          ]
        },
        {
          "nct": "NCT05132088",
          "url": "https://clinicaltrials.gov/study/NCT05132088",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 134,
              "ratePct": 25.4,
              "rowId": "7e635d49-1f9e-4d8d-a3c8-5e63b7b9550c"
            }
          ]
        },
        {
          "nct": "NCT06045221",
          "url": "https://clinicaltrials.gov/study/NCT06045221",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "7 mg Semaglutide",
              "nAtRisk": 426,
              "ratePct": 13.1,
              "rowId": "1226f9d7-d990-4631-92e2-a16bb433c1be"
            },
            {
              "arm": "14 mg Semaglutide",
              "nAtRisk": 425,
              "ratePct": 21.2,
              "rowId": "d3eae795-5409-43e5-9e08-c66f0d0d19c1"
            }
          ]
        }
      ]
    },
    {
      "effect": "nausea",
      "effectName": "Nausea",
      "row": "semaglutide_injectable",
      "rowLabel": "Semaglutide (injectable)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 31.3,
      "ciLowPct": 12,
      "ciHighPct": 59,
      "statedRates": 22,
      "distinctTrials": 15,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 15
      },
      "indicationMix": {
        "cvot": 1,
        "t2d": 6,
        "obesity": 8
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "ok",
        "ratePct": 39.3,
        "ciLowPct": 16,
        "ciHighPct": 68,
        "statedRates": 11,
        "distinctTrials": 8,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01720446",
          "url": "https://clinicaltrials.gov/study/NCT01720446",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 826,
              "ratePct": 17.3,
              "rowId": "b2b06520-3fc1-4bcc-9574-0ae8d1b70fc3"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 822,
              "ratePct": 21.8,
              "rowId": "c0669ffd-7b8b-4605-b133-676c41a36f83"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Sema 1.0 mg",
              "nAtRisk": 404,
              "ratePct": 22.3,
              "rowId": "9fa7bb92-cbf5-4e94-bbb5-d5c3a75afce6"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 301,
              "ratePct": 22.3,
              "rowId": "5b4e65f8-3999-4b12-882f-26bb0f5bd9a9"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 300,
              "ratePct": 21,
              "rowId": "3b353af0-46d4-4fe9-b9b6-5c236b916ebf"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 289,
              "ratePct": 21.5,
              "rowId": "aff64a7d-9651-4e30-bcdc-ef0b46a0bf4e"
            }
          ]
        },
        {
          "nct": "NCT03548935",
          "url": "https://clinicaltrials.gov/study/NCT03548935",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Sema 2.4 mg",
              "nAtRisk": 1306,
              "ratePct": 44.1,
              "rowId": "069df774-5dd1-4caf-ad72-a61fafae972a"
            }
          ]
        },
        {
          "nct": "NCT03552757",
          "url": "https://clinicaltrials.gov/study/NCT03552757",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 402,
              "ratePct": 31.8,
              "rowId": "364fb92a-b203-4b17-b8fe-f591a69cb261"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 403,
              "ratePct": 33.5,
              "rowId": "c96c58bc-1606-49c4-b56d-a19c0f7ece1c"
            }
          ]
        },
        {
          "nct": "NCT03611582",
          "url": "https://clinicaltrials.gov/study/NCT03611582",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 407,
              "ratePct": 58.2,
              "rowId": "a7f0b751-b72e-47c3-be8c-07468aaa4b8b"
            }
          ]
        },
        {
          "nct": "NCT03811574",
          "url": "https://clinicaltrials.gov/study/NCT03811574",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.7 mg",
              "nAtRisk": 100,
              "ratePct": 18,
              "rowId": "c95ef208-2ff3-43d5-9646-9bb5f5cbb853"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 199,
              "ratePct": 17.6,
              "rowId": "808c353c-09f9-4587-a76e-3e4691400879"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1 mg Semaglutide",
              "nAtRisk": 469,
              "ratePct": 17.9,
              "rowId": "cdb049ac-7c37-4e25-9228-ae208911b812"
            }
          ]
        },
        {
          "nct": "NCT03989232",
          "url": "https://clinicaltrials.gov/study/NCT03989232",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 480,
              "ratePct": 14.6,
              "rowId": "e5628ea9-205a-4fe2-8b54-e2fad62a160f"
            },
            {
              "arm": "Semaglutide 2.0 mg",
              "nAtRisk": 479,
              "ratePct": 14.4,
              "rowId": "539140b2-d8ab-4896-bf49-3c73a7318f13"
            }
          ]
        },
        {
          "nct": "NCT04788511",
          "url": "https://clinicaltrials.gov/study/NCT04788511",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 263,
              "ratePct": 17.1,
              "rowId": "80a43c25-ef55-4398-9b76-d147a72cbb72"
            }
          ]
        },
        {
          "nct": "NCT05064735",
          "url": "https://clinicaltrials.gov/study/NCT05064735",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 269,
              "ratePct": 21.9,
              "rowId": "4f9b07b9-c5d3-40b2-88f0-227e98cc1ebc"
            }
          ]
        },
        {
          "nct": "NCT05646706",
          "url": "https://clinicaltrials.gov/study/NCT05646706",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 1004,
              "ratePct": 43.7,
              "rowId": "539d9044-23c4-41f6-af8b-193beb7f3ca1"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 201,
              "ratePct": 38.3,
              "rowId": "5eabaae2-cbd3-480f-bc1c-1f04ba0b7ea7"
            }
          ]
        },
        {
          "nct": "NCT05649137",
          "url": "https://clinicaltrials.gov/study/NCT05649137",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 307,
              "ratePct": 29,
              "rowId": "e2222969-5750-4571-8807-221d05a517bf"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 103,
              "ratePct": 28.2,
              "rowId": "b2b9bcbc-5a2b-421e-8d88-17ff0c1f7a28"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "2.4 mg or MTD - Semaglutide",
              "nAtRisk": 376,
              "ratePct": 44.4,
              "rowId": "3d8ef5bd-6b5e-443c-9544-776061e03eb6"
            }
          ]
        }
      ]
    },
    {
      "effect": "nausea",
      "effectName": "Nausea",
      "row": "tirzepatide",
      "rowLabel": "Tirzepatide",
      "drug": "tirzepatide",
      "status": "ok",
      "ratePct": 25.3,
      "ciLowPct": 12,
      "ciHighPct": 46,
      "statedRates": 27,
      "distinctTrials": 13,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 12,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 7,
        "obesity": 5,
        "cvot": 1
      },
      "dominantTrial": {
        "nct": "NCT04255433",
        "weightPct": 67.2
      },
      "obesityOnly": {
        "status": "ok",
        "ratePct": 31.5,
        "ciLowPct": 15,
        "ciHighPct": 55,
        "statedRates": 8,
        "distinctTrials": 5,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT03861039",
          "url": "https://clinicaltrials.gov/study/NCT03861039",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 9.5,
              "rowId": "f79000f3-69ad-4782-8c04-82c3e4ae0b9b"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 147,
              "ratePct": 13.6,
              "rowId": "08640b93-1cd9-4b47-ad30-2e6546e11065"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 27,
              "rowId": "a2b20f3a-8fce-4a79-9ed6-261de5922b1a"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 159,
              "ratePct": 11.9,
              "rowId": "261838b3-6275-4cfe-b0e2-3f445e90bee6"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 158,
              "ratePct": 19.6,
              "rowId": "3e3e06c7-b943-49b3-b4d4-03cc8937b1ee"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 160,
              "ratePct": 20,
              "rowId": "6d2e1b67-0d42-4736-83bf-9454dd4f9c99"
            }
          ]
        },
        {
          "nct": "NCT03954834",
          "url": "https://clinicaltrials.gov/study/NCT03954834",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 11.6,
              "rowId": "4fe9a08f-1e8f-4e0a-9faf-b0b319635c05"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 13.2,
              "rowId": "180c7653-8e5e-4e50-a8e2-cb030ef50f28"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 18.2,
              "rowId": "81e43b15-008c-4873-84ce-0692a2f2ee44"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 17.4,
              "rowId": "3c7085f9-731c-4a3d-9ab2-9c5e885c9aff"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 469,
              "ratePct": 19.2,
              "rowId": "dc48b462-0680-4f7e-8d19-cd7530a605ce"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 22.1,
              "rowId": "08f1536e-89f1-47e2-8056-371023313d3f"
            }
          ]
        },
        {
          "nct": "NCT04039503",
          "url": "https://clinicaltrials.gov/study/NCT04039503",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 116,
              "ratePct": 12.9,
              "rowId": "4ee466c3-2a3d-4d84-a125-ee03951f2fcc"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 119,
              "ratePct": 17.6,
              "rowId": "4f8972bd-4b1c-4c95-9859-929d19dbda95"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 120,
              "ratePct": 18.3,
              "rowId": "1f183468-0a50-41c6-a6dd-1bdf7f46315a"
            }
          ]
        },
        {
          "nct": "NCT04184622",
          "url": "https://clinicaltrials.gov/study/NCT04184622",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 25.4,
              "rowId": "c5cedc26-82cf-413c-9651-5ef32252af3a"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 636,
              "ratePct": 34.1,
              "rowId": "8a4ede88-acca-4237-b0d0-f748b8c74e79"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 31.9,
              "rowId": "b6c2f470-b19b-47c1-b794-d44ab616d86f"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Tirzepatide (MTD)",
              "nAtRisk": 6647,
              "ratePct": 25,
              "rowId": "1715ac09-0cfe-43a8-871f-b93b98dd3014"
            }
          ]
        },
        {
          "nct": "NCT04657003",
          "url": "https://clinicaltrials.gov/study/NCT04657003",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 312,
              "ratePct": 20.2,
              "rowId": "01a4d1af-ba09-4b55-a5d3-54ce0ffd4bae"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 311,
              "ratePct": 21.9,
              "rowId": "28c7970c-6f4d-4b6d-8c10-a68815f58383"
            }
          ]
        },
        {
          "nct": "NCT04657016",
          "url": "https://clinicaltrials.gov/study/NCT04657016",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide",
              "nAtRisk": 287,
              "ratePct": 39.7,
              "rowId": "7ec0b3bf-2718-4915-9ee0-35bd8d9ea5dc"
            }
          ]
        },
        {
          "nct": "NCT04847557",
          "url": "https://clinicaltrials.gov/study/NCT04847557",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide - MTD",
              "nAtRisk": 364,
              "ratePct": 17,
              "rowId": "33a4d433-4203-42ec-998b-c7b21d3772a6"
            }
          ]
        },
        {
          "nct": "NCT05412004",
          "url": "https://clinicaltrials.gov/study/NCT05412004",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide MTD_GPI1",
              "nAtRisk": 114,
              "ratePct": 25.4,
              "rowId": "8dc7941b-630a-4875-bccf-df4aaf88dec5"
            },
            {
              "arm": "Tirzepatide MTD_GPI2",
              "nAtRisk": 119,
              "ratePct": 21.8,
              "rowId": "16ba50fe-1ab3-4032-9b66-c0c2d23efac9"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "15 mg Tirzepatide or MTD",
              "nAtRisk": 139,
              "ratePct": 25.2,
              "rowId": "82fd523c-4979-4c61-b3e7-48b16f4136eb"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "15 mg or MTD - Tirzepatide",
              "nAtRisk": 374,
              "ratePct": 43.6,
              "rowId": "6866f1ba-88c2-4b0d-b9b3-e8cc10a1d16e"
            }
          ]
        }
      ]
    },
    {
      "effect": "nausea",
      "effectName": "Nausea",
      "row": "liraglutide",
      "rowLabel": "Liraglutide",
      "drug": "liraglutide",
      "status": "ok",
      "ratePct": 21.3,
      "ciLowPct": 6,
      "ciHighPct": 56,
      "statedRates": 19,
      "distinctTrials": 13,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 12,
        "PHASE4": 1
      },
      "indicationMix": {
        "obesity": 3,
        "t2d": 7,
        "cvot": 1,
        "t1d_adjunct": 2
      },
      "dominantTrial": {
        "nct": "NCT01179048",
        "weightPct": 50.3
      },
      "obesityOnly": {
        "status": "ok",
        "ratePct": 40.8,
        "ciLowPct": 27,
        "ciHighPct": 56,
        "statedRates": 5,
        "distinctTrials": 3,
        "dominantTrial": {
          "nct": "NCT01272219",
          "weightPct": 70.6
        }
      },
      "trials": [
        {
          "nct": "NCT00781937",
          "url": "https://clinicaltrials.gov/study/NCT00781937",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Lira 3.0 mg",
              "nAtRisk": 212,
              "ratePct": 47.6,
              "rowId": "11a25ee2-f162-415b-b039-71f7a633fcee"
            }
          ]
        },
        {
          "nct": "NCT01029886",
          "url": "https://clinicaltrials.gov/study/NCT01029886",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide Once Daily",
              "nAtRisk": 450,
              "ratePct": 20.7,
              "rowId": "06f176d5-1257-4f74-9cd8-70616aebc481"
            }
          ]
        },
        {
          "nct": "NCT01179048",
          "url": "https://clinicaltrials.gov/study/NCT01179048",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 4668,
              "ratePct": 11.1,
              "rowId": "1ee0102f-9ce1-4162-afc4-5786764e40aa"
            }
          ]
        },
        {
          "nct": "NCT01272219",
          "url": "https://clinicaltrials.gov/study/NCT01272219",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg, Pre-diabetes",
              "nAtRisk": 1524,
              "ratePct": 40.8,
              "rowId": "0e4d1823-b84f-4cf5-a669-ec5c6594dba2"
            },
            {
              "arm": "Liraglutide 3.0 mg, no Pre-diabetes",
              "nAtRisk": 957,
              "ratePct": 43.7,
              "rowId": "31a5feee-d019-467e-9820-3601529a8ab2"
            }
          ]
        },
        {
          "nct": "NCT01272232",
          "url": "https://clinicaltrials.gov/study/NCT01272232",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg",
              "nAtRisk": 422,
              "ratePct": 32.7,
              "rowId": "6069f4fc-8619-4b37-b6b2-a97bab23c5ec"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 210,
              "ratePct": 31.4,
              "rowId": "15df1b82-e223-41ac-a457-be4815deffa5"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 137,
              "ratePct": 8,
              "rowId": "d322d985-2ffa-4bb0-89fe-e9f199b801a7"
            }
          ]
        },
        {
          "nct": "NCT01617434",
          "url": "https://clinicaltrials.gov/study/NCT01617434",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 225,
              "ratePct": 22.2,
              "rowId": "f8d3fd6e-68c2-4e6e-bc77-9e9626183c94"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.8 mg Liraglutide",
              "nAtRisk": 300,
              "ratePct": 18,
              "rowId": "f117afc1-6d77-4be4-a82b-31b33b543c0c"
            }
          ]
        },
        {
          "nct": "NCT01836523",
          "url": "https://clinicaltrials.gov/study/NCT01836523",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 350,
              "ratePct": 32,
              "rowId": "c0c9db3b-5304-49a2-85a7-29f67ce7172e"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 348,
              "ratePct": 40.5,
              "rowId": "07b8bf9e-c08d-4d00-9161-20dd5973a593"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 347,
              "ratePct": 49.6,
              "rowId": "3016e0e6-39cb-4a8e-9cd3-c5cc5c98db42"
            }
          ]
        },
        {
          "nct": "NCT01973231",
          "url": "https://clinicaltrials.gov/study/NCT01973231",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 202,
              "ratePct": 21.8,
              "rowId": "cf536541-be32-47f5-84d7-a1f486764b9b"
            }
          ]
        },
        {
          "nct": "NCT02098395",
          "url": "https://clinicaltrials.gov/study/NCT02098395",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 211,
              "ratePct": 32.2,
              "rowId": "d6acf859-d2a5-4bf1-b2db-5a20a4efe7ec"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 209,
              "ratePct": 46.4,
              "rowId": "10345ee9-151d-40f1-bf11-09de4673208a"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 206,
              "ratePct": 49.5,
              "rowId": "443e0ccb-6743-4d50-9721-9fdd301a4214"
            }
          ]
        },
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 284,
              "ratePct": 18,
              "rowId": "6b952cbb-cff1-46ba-807f-9396de18de37"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 287,
              "ratePct": 15.7,
              "rowId": "de143939-52b2-46dd-ac89-ba9f54a781ac"
            }
          ]
        }
      ]
    },
    {
      "effect": "nausea",
      "effectName": "Nausea",
      "row": "dulaglutide",
      "rowLabel": "Dulaglutide",
      "drug": "dulaglutide",
      "status": "ok",
      "ratePct": 18.2,
      "ciLowPct": 10,
      "ciHighPct": 31,
      "statedRates": 17,
      "distinctTrials": 12,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 10,
        "PHASE4": 1,
        "PHASE2": 1
      },
      "indicationMix": {
        "cvot": 2,
        "t2d": 9,
        "other": 1
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01394952",
          "url": "https://clinicaltrials.gov/study/NCT01394952",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Dulaglutide",
              "nAtRisk": 4943,
              "ratePct": 14.9,
              "rowId": "e9073601-7b8c-470e-9d95-17f98a402f13"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "LY2189265",
              "nAtRisk": 280,
              "ratePct": 6.1,
              "rowId": "dcfd9552-7b82-466e-aac2-71a71e4db439"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.5 mg LY2189265",
              "nAtRisk": 299,
              "ratePct": 20.4,
              "rowId": "58eabc8e-6d25-46f1-bb7c-c7286f9a9b4a"
            }
          ]
        },
        {
          "nct": "NCT02597049",
          "url": "https://clinicaltrials.gov/study/NCT02597049",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.5 mg Dulaglutide",
              "nAtRisk": 142,
              "ratePct": 14.8,
              "rowId": "ad07dc8e-972a-4443-8d5b-e92f1f95b8cc"
            },
            {
              "arm": "0.75 mg Dulaglutide",
              "nAtRisk": 141,
              "ratePct": 5,
              "rowId": "07b3fc7b-0dd8-43f3-8a0f-7e67f6e0240b"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 299,
              "ratePct": 13,
              "rowId": "fe96046d-92c0-4535-aa73-bfda52e8425a"
            },
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 299,
              "ratePct": 20.1,
              "rowId": "fe80f85f-dcaf-4fca-b1dc-1e1eeb2eaf7b"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 65,
              "ratePct": 9.2,
              "rowId": "34f6b851-bd2a-41b5-9880-c4dbe788a453"
            }
          ]
        },
        {
          "nct": "NCT03495102",
          "url": "https://clinicaltrials.gov/study/NCT03495102",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 612,
              "ratePct": 14.2,
              "rowId": "9825d5aa-2e5b-4a4a-a4a4-95ea9d440b1c"
            },
            {
              "arm": "Dulaglutide 3 mg",
              "nAtRisk": 616,
              "ratePct": 16.1,
              "rowId": "c1180bca-49ae-4823-831b-d624dfcad327"
            },
            {
              "arm": "Dulaglutide 4.5 mg",
              "nAtRisk": 614,
              "ratePct": 17.3,
              "rowId": "5099cc16-7ec3-4fc0-8943-0ce26ca699f3"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "0.75 mg Dulaglutide",
              "nAtRisk": 159,
              "ratePct": 7.5,
              "rowId": "b70b3d2a-281d-465a-871f-3e971768aee6"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "1.5 mg Dulaglutide",
              "nAtRisk": 6647,
              "ratePct": 22.3,
              "rowId": "0169f04a-5152-4497-802d-15be77778e0c"
            }
          ]
        },
        {
          "nct": "NCT04809220",
          "url": "https://clinicaltrials.gov/study/NCT04809220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 391,
              "ratePct": 9,
              "rowId": "cfd9caa4-9647-44cf-90bb-d67a802e0667"
            },
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 195,
              "ratePct": 4.6,
              "rowId": "bc58ae9b-c4c5-4c1b-8f52-8c9a709bc55a"
            }
          ]
        },
        {
          "nct": "NCT05254418",
          "url": "https://clinicaltrials.gov/study/NCT05254418",
          "phase": "PHASE2",
          "indication": "other",
          "arms": [
            {
              "arm": "Dulagutide Arm",
              "nAtRisk": 7,
              "ratePct": 14.3,
              "rowId": "132b19e7-4254-4727-a975-4e9db993f1a2"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "4.5 mg Dulaglutide or MTD",
              "nAtRisk": 143,
              "ratePct": 18.9,
              "rowId": "8d23409e-8509-4b12-b0d8-d7512c6a185b"
            }
          ]
        }
      ]
    },
    {
      "effect": "nausea",
      "effectName": "Nausea",
      "row": "exenatide",
      "rowLabel": "Exenatide",
      "drug": "exenatide",
      "status": "ok",
      "ratePct": 15.7,
      "ciLowPct": 3,
      "ciHighPct": 55,
      "statedRates": 6,
      "distinctTrials": 5,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 5
      },
      "indicationMix": {
        "t2d": 4,
        "other": 1
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide",
              "nAtRisk": 316,
              "ratePct": 37.7,
              "rowId": "89be69de-ff6b-42a9-a7bd-f32ce087756e"
            }
          ]
        },
        {
          "nct": "NCT00917267",
          "url": "https://clinicaltrials.gov/study/NCT00917267",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide Once Weekly",
              "nAtRisk": 340,
              "ratePct": 9.4,
              "rowId": "5ceb67d6-e121-40a3-83a4-7a585bb82087"
            },
            {
              "arm": "Exenatide Twice Daily",
              "nAtRisk": 338,
              "ratePct": 21.6,
              "rowId": "4029aa62-b81d-4545-bac6-7a2e2d541a0e"
            }
          ]
        },
        {
          "nct": "NCT01029886",
          "url": "https://clinicaltrials.gov/study/NCT01029886",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide Once Weekly",
              "nAtRisk": 461,
              "ratePct": 9.3,
              "rowId": "5fde69bf-344e-473e-8c72-6cf66f8e2d63"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide ER",
              "nAtRisk": 405,
              "ratePct": 11.9,
              "rowId": "14991216-27ae-4137-8838-eb0e0e023792"
            }
          ]
        },
        {
          "nct": "NCT02229383",
          "url": "https://clinicaltrials.gov/study/NCT02229383",
          "phase": "PHASE3",
          "indication": "other",
          "arms": [
            {
              "arm": "Exenatide",
              "nAtRisk": 231,
              "ratePct": 5.2,
              "rowId": "7691b8c7-e445-4c74-81d0-7ea95aef70e7"
            }
          ]
        }
      ]
    },
    {
      "effect": "nausea",
      "effectName": "Nausea",
      "row": "lixisenatide",
      "rowLabel": "Lixisenatide",
      "drug": "lixisenatide",
      "status": "ok",
      "ratePct": 23.5,
      "ciLowPct": 16,
      "ciHighPct": 34,
      "statedRates": 9,
      "distinctTrials": 8,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 7,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 7,
        "cvot": 1
      },
      "dominantTrial": {
        "nct": "NCT01147250",
        "weightPct": 58
      },
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 318,
              "ratePct": 28.6,
              "rowId": "c7f6148f-7c39-4759-9082-b45555b9e92f"
            }
          ]
        },
        {
          "nct": "NCT00713830",
          "url": "https://clinicaltrials.gov/study/NCT00713830",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 574,
              "ratePct": 28,
              "rowId": "0ccea47d-d016-4eb5-b20f-555eaf61569d"
            }
          ]
        },
        {
          "nct": "NCT00715624",
          "url": "https://clinicaltrials.gov/study/NCT00715624",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 328,
              "ratePct": 29.3,
              "rowId": "31f10216-6368-445f-89bc-10a552c2a5c0"
            }
          ]
        },
        {
          "nct": "NCT00763815",
          "url": "https://clinicaltrials.gov/study/NCT00763815",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 323,
              "ratePct": 26,
              "rowId": "a3c772da-f9c9-4db3-9b8f-e4ea87035ff2"
            }
          ]
        },
        {
          "nct": "NCT00975286",
          "url": "https://clinicaltrials.gov/study/NCT00975286",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 223,
              "ratePct": 27.4,
              "rowId": "8f6df2da-d0bd-4f3f-9db2-fd105244ee95"
            }
          ]
        },
        {
          "nct": "NCT01147250",
          "url": "https://clinicaltrials.gov/study/NCT01147250",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 3031,
              "ratePct": 21.7,
              "rowId": "4ee6106a-1244-4758-9430-31b6018886b4"
            }
          ]
        },
        {
          "nct": "NCT01517412",
          "url": "https://clinicaltrials.gov/study/NCT01517412",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide Main Meal",
              "nAtRisk": 225,
              "ratePct": 14.7,
              "rowId": "36df6860-2795-4cfd-8039-a43d213d0419"
            },
            {
              "arm": "Lixisenatide Breakfast",
              "nAtRisk": 226,
              "ratePct": 15.5,
              "rowId": "430e84da-bd15-4209-a6b8-0a08d005b609"
            }
          ]
        },
        {
          "nct": "NCT01973231",
          "url": "https://clinicaltrials.gov/study/NCT01973231",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 202,
              "ratePct": 21.8,
              "rowId": "bf980f99-7f5a-4488-843a-353e22a62069"
            }
          ]
        }
      ]
    },
    {
      "effect": "vomiting",
      "effectName": "Vomiting",
      "row": "semaglutide_oral",
      "rowLabel": "Semaglutide (oral)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 12.4,
      "ciLowPct": 4,
      "ciHighPct": 32,
      "statedRates": 18,
      "distinctTrials": 9,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 9
      },
      "indicationMix": {
        "t2d": 7,
        "obesity": 2
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 2,
        "distinctTrials": 2,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 285,
              "ratePct": 8.4,
              "rowId": "82c50d1e-926d-47a2-8610-be9089cc7466"
            }
          ]
        },
        {
          "nct": "NCT02906930",
          "url": "https://clinicaltrials.gov/study/NCT02906930",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 175,
              "ratePct": 2.9,
              "rowId": "1c5435aa-c7f2-456a-b12b-025e6a035f89"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 175,
              "ratePct": 4.6,
              "rowId": "eb7665d2-e7b4-47d7-aef6-387893372d12"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 175,
              "ratePct": 6.9,
              "rowId": "94cfdb31-8606-4001-a035-79e80d4b4056"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 131,
              "ratePct": 2.3,
              "rowId": "ad960032-4534-4b0e-8b30-197a4651ed9e"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 132,
              "ratePct": 0.8,
              "rowId": "c6574717-e0df-4333-ae4b-e20add9361d3"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 130,
              "ratePct": 6.9,
              "rowId": "1f250d66-de59-44de-84e0-055e5fc4918b"
            }
          ]
        },
        {
          "nct": "NCT03021187",
          "url": "https://clinicaltrials.gov/study/NCT03021187",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 184,
              "ratePct": 6,
              "rowId": "cf4a5f4a-fb64-4b4f-9bd4-6b3e6681e20b"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 181,
              "ratePct": 7.7,
              "rowId": "11322f19-4261-4a5a-bc25-56d8b5e84df8"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 181,
              "ratePct": 9.4,
              "rowId": "aa699de2-c2be-4b43-8627-f4a4f37e3e70"
            }
          ]
        },
        {
          "nct": "NCT04596631",
          "url": "https://clinicaltrials.gov/study/NCT04596631",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide",
              "nAtRisk": 66,
              "ratePct": 19.7,
              "rowId": "39cbe3f5-8d09-4474-9d61-7ddd81c30c4e"
            }
          ]
        },
        {
          "nct": "NCT04707469",
          "url": "https://clinicaltrials.gov/study/NCT04707469",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 534,
              "ratePct": 9.7,
              "rowId": "1bdf92e5-5224-48c8-af90-11ab4215b76f"
            },
            {
              "arm": "Oral Semaglutide 25 mg",
              "nAtRisk": 534,
              "ratePct": 17,
              "rowId": "e0cc8aca-2b3a-4245-bd4a-5906efcdce6b"
            },
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 534,
              "ratePct": 18.2,
              "rowId": "176484b6-7a1d-4343-9641-67b40f8b35bc"
            }
          ]
        },
        {
          "nct": "NCT05035095",
          "url": "https://clinicaltrials.gov/study/NCT05035095",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 334,
              "ratePct": 24,
              "rowId": "c29b18a9-5a93-4d02-84ad-978d80bfcf22"
            }
          ]
        },
        {
          "nct": "NCT05132088",
          "url": "https://clinicaltrials.gov/study/NCT05132088",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 134,
              "ratePct": 14.9,
              "rowId": "d505be4c-222e-4043-9f21-b206b638403c"
            }
          ]
        },
        {
          "nct": "NCT06045221",
          "url": "https://clinicaltrials.gov/study/NCT06045221",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "7 mg Semaglutide",
              "nAtRisk": 426,
              "ratePct": 7.7,
              "rowId": "8e0ee0d1-9029-49a3-bbc2-c729d52026bb"
            },
            {
              "arm": "14 mg Semaglutide",
              "nAtRisk": 425,
              "ratePct": 10.4,
              "rowId": "73ef8555-f91e-4089-b6de-0c0960599f3f"
            }
          ]
        }
      ]
    },
    {
      "effect": "vomiting",
      "effectName": "Vomiting",
      "row": "semaglutide_injectable",
      "rowLabel": "Semaglutide (injectable)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 15.9,
      "ciLowPct": 7,
      "ciHighPct": 34,
      "statedRates": 22,
      "distinctTrials": 15,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 15
      },
      "indicationMix": {
        "cvot": 1,
        "t2d": 6,
        "obesity": 8
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "ok",
        "ratePct": 20,
        "ciLowPct": 9,
        "ciHighPct": 40,
        "statedRates": 11,
        "distinctTrials": 8,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01720446",
          "url": "https://clinicaltrials.gov/study/NCT01720446",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 826,
              "ratePct": 10.5,
              "rowId": "df0829af-e9b1-400e-91b6-84e8d6ffc2bb"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 822,
              "ratePct": 14.8,
              "rowId": "0f41d796-b0d9-4d2e-a7a3-0ef69f7755b0"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Sema 1.0 mg",
              "nAtRisk": 404,
              "ratePct": 7.2,
              "rowId": "12046557-1f14-4604-9623-8b5f297bca82"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 301,
              "ratePct": 10,
              "rowId": "78a5773c-3c0b-4a49-86f5-7f46864d06a8"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 300,
              "ratePct": 10.3,
              "rowId": "9ff74b62-ea89-4c93-af67-03e6e25e1a2d"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 289,
              "ratePct": 10,
              "rowId": "84f69e1e-bf57-47a8-97d2-84864b755bfa"
            }
          ]
        },
        {
          "nct": "NCT03548935",
          "url": "https://clinicaltrials.gov/study/NCT03548935",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Sema 2.4 mg",
              "nAtRisk": 1306,
              "ratePct": 24.6,
              "rowId": "afa6c8b0-5eef-4f46-ae57-aaa1c5259351"
            }
          ]
        },
        {
          "nct": "NCT03552757",
          "url": "https://clinicaltrials.gov/study/NCT03552757",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 402,
              "ratePct": 13.4,
              "rowId": "f449dc3c-4681-4dd7-bf82-6823efd60b46"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 403,
              "ratePct": 21.3,
              "rowId": "1279443c-4aca-438c-985b-d739227ffded"
            }
          ]
        },
        {
          "nct": "NCT03611582",
          "url": "https://clinicaltrials.gov/study/NCT03611582",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 407,
              "ratePct": 27.3,
              "rowId": "b0197da4-03c4-451f-83c6-9e4e0bded772"
            }
          ]
        },
        {
          "nct": "NCT03811574",
          "url": "https://clinicaltrials.gov/study/NCT03811574",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.7 mg",
              "nAtRisk": 100,
              "ratePct": 10,
              "rowId": "37d22092-7b57-4e60-9b41-fdc1a36fc086"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 199,
              "ratePct": 8.5,
              "rowId": "991ccbc0-b02b-4700-98e9-e7cc63a91695"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1 mg Semaglutide",
              "nAtRisk": 469,
              "ratePct": 8.3,
              "rowId": "55668e2d-a78d-421c-bbd5-c5accfb6caae"
            }
          ]
        },
        {
          "nct": "NCT03989232",
          "url": "https://clinicaltrials.gov/study/NCT03989232",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 480,
              "ratePct": 6.7,
              "rowId": "f7b97f4a-1290-46a6-872e-90108a784ae7"
            },
            {
              "arm": "Semaglutide 2.0 mg",
              "nAtRisk": 479,
              "ratePct": 7.7,
              "rowId": "ba2afc11-83ca-4828-9dc4-c2a7be67071d"
            }
          ]
        },
        {
          "nct": "NCT04788511",
          "url": "https://clinicaltrials.gov/study/NCT04788511",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 263,
              "ratePct": 6.5,
              "rowId": "235fbcaa-8bf6-4066-8fc4-387a7e1dde69"
            }
          ]
        },
        {
          "nct": "NCT05064735",
          "url": "https://clinicaltrials.gov/study/NCT05064735",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 269,
              "ratePct": 7.8,
              "rowId": "335b7baa-7a64-454d-b949-801451b0195e"
            }
          ]
        },
        {
          "nct": "NCT05646706",
          "url": "https://clinicaltrials.gov/study/NCT05646706",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 1004,
              "ratePct": 24.8,
              "rowId": "4ff3d34a-ea2c-48cf-b94f-10cbfbea2ddc"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 201,
              "ratePct": 16.4,
              "rowId": "bc2f3d85-d92b-4ffc-8bd7-dfc70163187c"
            }
          ]
        },
        {
          "nct": "NCT05649137",
          "url": "https://clinicaltrials.gov/study/NCT05649137",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 307,
              "ratePct": 16.6,
              "rowId": "f8dee23d-5fa8-4ee7-bf1a-876ff182d676"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 103,
              "ratePct": 13.6,
              "rowId": "f23b7c38-3730-4a35-8a6b-597a7bbf3ddb"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "2.4 mg or MTD - Semaglutide",
              "nAtRisk": 376,
              "ratePct": 21.3,
              "rowId": "9b7991fb-b33b-4f99-955e-bbcd8902c2f4"
            }
          ]
        }
      ]
    },
    {
      "effect": "vomiting",
      "effectName": "Vomiting",
      "row": "tirzepatide",
      "rowLabel": "Tirzepatide",
      "drug": "tirzepatide",
      "status": "ok",
      "ratePct": 11.2,
      "ciLowPct": 6,
      "ciHighPct": 21,
      "statedRates": 27,
      "distinctTrials": 13,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 12,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 7,
        "obesity": 5,
        "cvot": 1
      },
      "dominantTrial": {
        "nct": "NCT04255433",
        "weightPct": 67.2
      },
      "obesityOnly": {
        "status": "ok",
        "ratePct": 13.1,
        "ciLowPct": 9,
        "ciHighPct": 19,
        "statedRates": 8,
        "distinctTrials": 5,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT03861039",
          "url": "https://clinicaltrials.gov/study/NCT03861039",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 2.7,
              "rowId": "b171528a-331d-4c65-ba7e-be76a9e2ddbb"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 147,
              "ratePct": 7.5,
              "rowId": "1f729695-5efb-4f20-a225-3c20dfd641e5"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 10.1,
              "rowId": "29be1fd8-9d81-41c6-b79e-a65f1144c300"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 159,
              "ratePct": 8.2,
              "rowId": "9cbf2a60-2da5-4710-9165-5705eade5227"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 158,
              "ratePct": 5.1,
              "rowId": "fbdcfbf7-f937-4ad9-b193-67f4518b9397"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 160,
              "ratePct": 11.9,
              "rowId": "cf0640df-ee4e-48e4-9120-5561f3731e21"
            }
          ]
        },
        {
          "nct": "NCT03954834",
          "url": "https://clinicaltrials.gov/study/NCT03954834",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 3.3,
              "rowId": "06f5b093-4eae-423e-8e35-e009e35daef1"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 2.5,
              "rowId": "d93067a0-75c8-41a5-95a7-b965c448ddfb"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 5.8,
              "rowId": "86a534fb-5ff1-415e-b476-78d1184252de"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 5.7,
              "rowId": "c9006aa5-23a3-4fe2-9bfb-1b01d9b48ffa"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 469,
              "ratePct": 8.3,
              "rowId": "18e587fc-12ee-4455-bf43-5115bfffd868"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 9.8,
              "rowId": "a881085a-8cb3-4a26-ae24-51aa37d9a2e5"
            }
          ]
        },
        {
          "nct": "NCT04039503",
          "url": "https://clinicaltrials.gov/study/NCT04039503",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 116,
              "ratePct": 6.9,
              "rowId": "1601594e-44fb-43d8-a9e4-8703e0c798fb"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 119,
              "ratePct": 7.6,
              "rowId": "aaf3c43f-c3f0-473d-b0a8-b2f126be3b1c"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 120,
              "ratePct": 12.5,
              "rowId": "d91e2bd5-aba3-439a-ad15-f1f37f1d5289"
            }
          ]
        },
        {
          "nct": "NCT04184622",
          "url": "https://clinicaltrials.gov/study/NCT04184622",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 9.2,
              "rowId": "9c05d067-d1f9-491b-9e04-dfb89f34434e"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 636,
              "ratePct": 11.6,
              "rowId": "8e7924fa-7a74-4faf-998e-c3f436e16990"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 12.9,
              "rowId": "61a63247-19d8-4562-b36b-3685563aa2bb"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Tirzepatide (MTD)",
              "nAtRisk": 6647,
              "ratePct": 11.4,
              "rowId": "592f028c-595e-4056-9256-193e983b4416"
            }
          ]
        },
        {
          "nct": "NCT04657003",
          "url": "https://clinicaltrials.gov/study/NCT04657003",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 312,
              "ratePct": 10.9,
              "rowId": "961379de-629b-44dc-addf-8fb39897592b"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 311,
              "ratePct": 12.9,
              "rowId": "895e208d-f552-48b3-97bf-d3e8294f52e2"
            }
          ]
        },
        {
          "nct": "NCT04657016",
          "url": "https://clinicaltrials.gov/study/NCT04657016",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide",
              "nAtRisk": 287,
              "ratePct": 18.1,
              "rowId": "b193549d-04f0-4d84-b95c-b575c9d3854d"
            }
          ]
        },
        {
          "nct": "NCT04847557",
          "url": "https://clinicaltrials.gov/study/NCT04847557",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide - MTD",
              "nAtRisk": 364,
              "ratePct": 10.4,
              "rowId": "7dd4beef-272a-4a80-8ea4-391797cbe307"
            }
          ]
        },
        {
          "nct": "NCT05412004",
          "url": "https://clinicaltrials.gov/study/NCT05412004",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide MTD_GPI1",
              "nAtRisk": 114,
              "ratePct": 17.5,
              "rowId": "93df4693-892b-4352-a34b-3722823e23a5"
            },
            {
              "arm": "Tirzepatide MTD_GPI2",
              "nAtRisk": 119,
              "ratePct": 9.2,
              "rowId": "03b5a707-bd42-460e-a1e7-c2b74907e56f"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "15 mg Tirzepatide or MTD",
              "nAtRisk": 139,
              "ratePct": 6.5,
              "rowId": "96a7e6f0-e907-438e-b7e6-899d59dd1874"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "15 mg or MTD - Tirzepatide",
              "nAtRisk": 374,
              "ratePct": 15,
              "rowId": "fe5fdeef-59a5-4a2d-9cfb-a0a6e45e8e0a"
            }
          ]
        }
      ]
    },
    {
      "effect": "vomiting",
      "effectName": "Vomiting",
      "row": "liraglutide",
      "rowLabel": "Liraglutide",
      "drug": "liraglutide",
      "status": "ok",
      "ratePct": 12.8,
      "ciLowPct": 6,
      "ciHighPct": 25,
      "statedRates": 18,
      "distinctTrials": 12,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 11,
        "PHASE4": 1
      },
      "indicationMix": {
        "obesity": 3,
        "t2d": 7,
        "t1d_adjunct": 2
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "ok",
        "ratePct": 17.4,
        "ciLowPct": 13,
        "ciHighPct": 24,
        "statedRates": 5,
        "distinctTrials": 3,
        "dominantTrial": {
          "nct": "NCT01272219",
          "weightPct": 70.6
        }
      },
      "trials": [
        {
          "nct": "NCT00781937",
          "url": "https://clinicaltrials.gov/study/NCT00781937",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Lira 3.0 mg",
              "nAtRisk": 212,
              "ratePct": 16.5,
              "rowId": "9e6de2b4-71d9-4bb2-8038-ff587cbe4cb8"
            }
          ]
        },
        {
          "nct": "NCT01029886",
          "url": "https://clinicaltrials.gov/study/NCT01029886",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide Once Daily",
              "nAtRisk": 450,
              "ratePct": 10.4,
              "rowId": "df349137-0b0f-4e9e-a76e-b38636738d75"
            }
          ]
        },
        {
          "nct": "NCT01272219",
          "url": "https://clinicaltrials.gov/study/NCT01272219",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg, Pre-diabetes",
              "nAtRisk": 1524,
              "ratePct": 19.7,
              "rowId": "6be0db12-a972-4dcb-9504-6508285fd910"
            },
            {
              "arm": "Liraglutide 3.0 mg, no Pre-diabetes",
              "nAtRisk": 957,
              "ratePct": 18,
              "rowId": "84c86516-1da6-4d77-ae5c-ce73ef48dc3c"
            }
          ]
        },
        {
          "nct": "NCT01272232",
          "url": "https://clinicaltrials.gov/study/NCT01272232",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg",
              "nAtRisk": 422,
              "ratePct": 15.6,
              "rowId": "f6f6c2c0-1b47-42fc-b326-51e8aa2bd403"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 210,
              "ratePct": 10,
              "rowId": "3aab4941-803b-417f-8614-bf3fb344e670"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 137,
              "ratePct": 0.7,
              "rowId": "3497e0be-de76-4b1e-96dd-9b5f8fd67bde"
            }
          ]
        },
        {
          "nct": "NCT01617434",
          "url": "https://clinicaltrials.gov/study/NCT01617434",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 225,
              "ratePct": 8.9,
              "rowId": "d119ac41-e256-444d-a855-cc46408df16d"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.8 mg Liraglutide",
              "nAtRisk": 300,
              "ratePct": 8.3,
              "rowId": "b8e9b07a-4ae5-462d-ae74-aec71d0e88fa"
            }
          ]
        },
        {
          "nct": "NCT01836523",
          "url": "https://clinicaltrials.gov/study/NCT01836523",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 350,
              "ratePct": 6.9,
              "rowId": "98f459db-7a4d-4ebd-863d-17d8165e47ec"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 348,
              "ratePct": 12.6,
              "rowId": "0269f69c-7eaa-43f8-bd99-a6443920d3ad"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 347,
              "ratePct": 18.4,
              "rowId": "18f7488c-7d66-4e6a-b411-1fb078b3602a"
            }
          ]
        },
        {
          "nct": "NCT01973231",
          "url": "https://clinicaltrials.gov/study/NCT01973231",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 202,
              "ratePct": 6.9,
              "rowId": "1d8cce94-5ba8-401b-acb9-ebd793d167ea"
            }
          ]
        },
        {
          "nct": "NCT02098395",
          "url": "https://clinicaltrials.gov/study/NCT02098395",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 211,
              "ratePct": 9,
              "rowId": "68921c66-7278-4048-8bcf-378c58ff5b34"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 209,
              "ratePct": 13.9,
              "rowId": "f51fbd27-03de-4527-b9bc-b952683334b5"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 206,
              "ratePct": 17,
              "rowId": "3cf33536-70ac-4625-aab6-c31202f19ece"
            }
          ]
        },
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 284,
              "ratePct": 4.6,
              "rowId": "5b1d1f3b-ad9f-4f0a-81f6-572afe48afee"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 287,
              "ratePct": 8,
              "rowId": "35ab9336-f5aa-48d6-a594-c8ad6a404286"
            }
          ]
        }
      ]
    },
    {
      "effect": "vomiting",
      "effectName": "Vomiting",
      "row": "dulaglutide",
      "rowLabel": "Dulaglutide",
      "drug": "dulaglutide",
      "status": "ok",
      "ratePct": 7.9,
      "ciLowPct": 3,
      "ciHighPct": 18,
      "statedRates": 14,
      "distinctTrials": 10,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 9,
        "PHASE4": 1
      },
      "indicationMix": {
        "cvot": 2,
        "t2d": 8
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01394952",
          "url": "https://clinicaltrials.gov/study/NCT01394952",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Dulaglutide",
              "nAtRisk": 4943,
              "ratePct": 6.6,
              "rowId": "687f4f6b-daee-4480-a075-06462354acce"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "LY2189265",
              "nAtRisk": 280,
              "ratePct": 1.8,
              "rowId": "6ddef36e-6fa6-4f26-8aaa-308fc144676e"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.5 mg LY2189265",
              "nAtRisk": 299,
              "ratePct": 7,
              "rowId": "8640478e-797e-4ede-90ff-501196b36e21"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 299,
              "ratePct": 4,
              "rowId": "6b1790bc-915c-477f-a569-f9baabe743b7"
            },
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 299,
              "ratePct": 9.7,
              "rowId": "499bfcce-2fbe-41c1-8353-f771a9c113e2"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 65,
              "ratePct": 1.5,
              "rowId": "92b490a7-8572-4dbb-ac79-07107c44dc5a"
            }
          ]
        },
        {
          "nct": "NCT03495102",
          "url": "https://clinicaltrials.gov/study/NCT03495102",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 612,
              "ratePct": 6.5,
              "rowId": "b1756822-9490-4146-979f-d6375a6cdede"
            },
            {
              "arm": "Dulaglutide 3 mg",
              "nAtRisk": 616,
              "ratePct": 9.3,
              "rowId": "40411bd2-cd43-4e00-a8e5-52fd3446e6e0"
            },
            {
              "arm": "Dulaglutide 4.5 mg",
              "nAtRisk": 614,
              "ratePct": 10.4,
              "rowId": "e10d6de4-ed97-4efc-9a9c-458d0dbdf0ec"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "0.75 mg Dulaglutide",
              "nAtRisk": 159,
              "ratePct": 1.3,
              "rowId": "484017ee-2e39-484b-bc24-edd4b232bd7b"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "1.5 mg Dulaglutide",
              "nAtRisk": 6647,
              "ratePct": 9.6,
              "rowId": "afcb396e-e426-4685-a66d-d24174c2c6d5"
            }
          ]
        },
        {
          "nct": "NCT04809220",
          "url": "https://clinicaltrials.gov/study/NCT04809220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 391,
              "ratePct": 2.8,
              "rowId": "ee28cf1e-8e40-4045-be09-1da82382494a"
            },
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 195,
              "ratePct": 1,
              "rowId": "a2b52be3-b8ad-4ccd-858c-367bb129c9c9"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "4.5 mg Dulaglutide or MTD",
              "nAtRisk": 143,
              "ratePct": 9.8,
              "rowId": "e1545cce-834d-465b-9f25-da29054cf788"
            }
          ]
        }
      ]
    },
    {
      "effect": "vomiting",
      "effectName": "Vomiting",
      "row": "exenatide",
      "rowLabel": "Exenatide",
      "drug": "exenatide",
      "status": "ok",
      "ratePct": 8.2,
      "ciLowPct": 2,
      "ciHighPct": 25,
      "statedRates": 5,
      "distinctTrials": 4,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 4
      },
      "indicationMix": {
        "t2d": 4
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide",
              "nAtRisk": 316,
              "ratePct": 15.5,
              "rowId": "a49439d3-3742-44e9-824b-a11cca3d4fad"
            }
          ]
        },
        {
          "nct": "NCT00917267",
          "url": "https://clinicaltrials.gov/study/NCT00917267",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide Once Weekly",
              "nAtRisk": 340,
              "ratePct": 7.9,
              "rowId": "39b47b0c-cf0e-45f1-9c7e-cd621441be04"
            },
            {
              "arm": "Exenatide Twice Daily",
              "nAtRisk": 338,
              "ratePct": 11.5,
              "rowId": "38eb7353-a371-4612-8169-db9973b32322"
            }
          ]
        },
        {
          "nct": "NCT01029886",
          "url": "https://clinicaltrials.gov/study/NCT01029886",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide Once Weekly",
              "nAtRisk": 461,
              "ratePct": 3.7,
              "rowId": "f748f532-02f4-43d8-9de6-e6d15e3d7d95"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide ER",
              "nAtRisk": 405,
              "ratePct": 6.2,
              "rowId": "05ca7733-a532-4a85-a92c-c08214c583cd"
            }
          ]
        }
      ]
    },
    {
      "effect": "vomiting",
      "effectName": "Vomiting",
      "row": "lixisenatide",
      "rowLabel": "Lixisenatide",
      "drug": "lixisenatide",
      "status": "ok",
      "ratePct": 9.1,
      "ciLowPct": 7,
      "ciHighPct": 12,
      "statedRates": 7,
      "distinctTrials": 7,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 6,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 6,
        "cvot": 1
      },
      "dominantTrial": {
        "nct": "NCT01147250",
        "weightPct": 60.6
      },
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 318,
              "ratePct": 12.9,
              "rowId": "74d12d44-1008-4a0e-ae1f-cc8aad8bc377"
            }
          ]
        },
        {
          "nct": "NCT00713830",
          "url": "https://clinicaltrials.gov/study/NCT00713830",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 574,
              "ratePct": 10.6,
              "rowId": "a3e6e0ef-a745-404a-9a43-c3a63deaaa71"
            }
          ]
        },
        {
          "nct": "NCT00715624",
          "url": "https://clinicaltrials.gov/study/NCT00715624",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 328,
              "ratePct": 9.8,
              "rowId": "1bc773df-f6ab-4949-9046-35e1203127e8"
            }
          ]
        },
        {
          "nct": "NCT00763815",
          "url": "https://clinicaltrials.gov/study/NCT00763815",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 323,
              "ratePct": 8,
              "rowId": "b2f00a34-17d0-49c6-9362-64f50a6f8fe6"
            }
          ]
        },
        {
          "nct": "NCT00975286",
          "url": "https://clinicaltrials.gov/study/NCT00975286",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 223,
              "ratePct": 9.4,
              "rowId": "5ffa39be-a876-45b6-9416-863e392b5a0f"
            }
          ]
        },
        {
          "nct": "NCT01147250",
          "url": "https://clinicaltrials.gov/study/NCT01147250",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 3031,
              "ratePct": 8.5,
              "rowId": "e0d1a647-7a33-4c89-a01f-2508400a924e"
            }
          ]
        },
        {
          "nct": "NCT01973231",
          "url": "https://clinicaltrials.gov/study/NCT01973231",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 202,
              "ratePct": 8.9,
              "rowId": "d9b210e7-a332-4ea5-8d4e-4e9200a9780b"
            }
          ]
        }
      ]
    },
    {
      "effect": "diarrhea",
      "effectName": "Diarrhoea",
      "row": "semaglutide_oral",
      "rowLabel": "Semaglutide (oral)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 14.7,
      "ciLowPct": 6,
      "ciHighPct": 33,
      "statedRates": 21,
      "distinctTrials": 10,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 10
      },
      "indicationMix": {
        "t2d": 8,
        "obesity": 2
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 2,
        "distinctTrials": 2,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 285,
              "ratePct": 15.1,
              "rowId": "7cb86d6b-631d-47d3-81bb-30b4d339155b"
            }
          ]
        },
        {
          "nct": "NCT02906930",
          "url": "https://clinicaltrials.gov/study/NCT02906930",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 175,
              "ratePct": 8.6,
              "rowId": "16795632-3956-4409-a617-e42683c484da"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 175,
              "ratePct": 5.1,
              "rowId": "a95159ae-ae1b-4778-a4e9-be6bf74270f0"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 175,
              "ratePct": 5.1,
              "rowId": "84fa9480-a41b-4e5b-810b-980126370109"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 131,
              "ratePct": 1.5,
              "rowId": "a36f3171-9dac-4576-923f-e8ae44dc8aa4"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 132,
              "ratePct": 1.5,
              "rowId": "b4a1e699-54ac-4f4d-9c40-7af33d470309"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 130,
              "ratePct": 7.7,
              "rowId": "f9972d37-dd98-43d5-85f0-4741389b8a23"
            }
          ]
        },
        {
          "nct": "NCT03021187",
          "url": "https://clinicaltrials.gov/study/NCT03021187",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 184,
              "ratePct": 8.7,
              "rowId": "71f9f9e8-ccd7-4767-b09c-5736047965d5"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 181,
              "ratePct": 12.2,
              "rowId": "0b2db09d-f4b5-4a08-93b3-699dbafa1788"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 181,
              "ratePct": 14.4,
              "rowId": "cf16dcc8-d767-49a5-ad2a-25ef0cf487ae"
            }
          ]
        },
        {
          "nct": "NCT04109547",
          "url": "https://clinicaltrials.gov/study/NCT04109547",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 130,
              "ratePct": 3.1,
              "rowId": "a4833f6a-8e88-4354-ba34-c9492afbff0a"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 130,
              "ratePct": 9.2,
              "rowId": "f86e374b-be28-41b3-9aef-a6cef72facf2"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 129,
              "ratePct": 9.3,
              "rowId": "53e2b635-9299-4ccd-aad2-4863886a94b6"
            }
          ]
        },
        {
          "nct": "NCT04596631",
          "url": "https://clinicaltrials.gov/study/NCT04596631",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide",
              "nAtRisk": 66,
              "ratePct": 22.7,
              "rowId": "8a341e27-6b3e-4a5f-84f1-963b6c964d02"
            }
          ]
        },
        {
          "nct": "NCT04707469",
          "url": "https://clinicaltrials.gov/study/NCT04707469",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 534,
              "ratePct": 12.4,
              "rowId": "fdfba0dc-2cfa-4a48-ae4e-ea891a793574"
            },
            {
              "arm": "Oral Semaglutide 25 mg",
              "nAtRisk": 534,
              "ratePct": 12.9,
              "rowId": "c640a652-9177-42cf-b4a5-993e8144265f"
            },
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 534,
              "ratePct": 14.2,
              "rowId": "8488d34f-c53c-468a-83f7-0123f7e3da95"
            }
          ]
        },
        {
          "nct": "NCT05035095",
          "url": "https://clinicaltrials.gov/study/NCT05035095",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 334,
              "ratePct": 26.6,
              "rowId": "dcd67493-ca73-4d76-8f69-c5352d79f438"
            }
          ]
        },
        {
          "nct": "NCT05132088",
          "url": "https://clinicaltrials.gov/study/NCT05132088",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 134,
              "ratePct": 16.4,
              "rowId": "78364e7b-277a-40f4-92fa-4de2a6bfdedb"
            }
          ]
        },
        {
          "nct": "NCT06045221",
          "url": "https://clinicaltrials.gov/study/NCT06045221",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "7 mg Semaglutide",
              "nAtRisk": 426,
              "ratePct": 13.1,
              "rowId": "913c8ff1-c15a-4d27-8289-46055adc1664"
            },
            {
              "arm": "14 mg Semaglutide",
              "nAtRisk": 425,
              "ratePct": 18.1,
              "rowId": "58821c5f-e00c-4af7-8bdd-3dd19b117526"
            }
          ]
        }
      ]
    },
    {
      "effect": "diarrhea",
      "effectName": "Diarrhoea",
      "row": "semaglutide_injectable",
      "rowLabel": "Semaglutide (injectable)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 21,
      "ciLowPct": 9,
      "ciHighPct": 42,
      "statedRates": 22,
      "distinctTrials": 15,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 15
      },
      "indicationMix": {
        "cvot": 1,
        "t2d": 6,
        "obesity": 8
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "ok",
        "ratePct": 25.9,
        "ciLowPct": 11,
        "ciHighPct": 49,
        "statedRates": 11,
        "distinctTrials": 8,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01720446",
          "url": "https://clinicaltrials.gov/study/NCT01720446",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 826,
              "ratePct": 17.9,
              "rowId": "7264a628-1c19-48b5-98e2-dc197a7a44bc"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 822,
              "ratePct": 18,
              "rowId": "e10916a2-d5c8-4173-a08c-6ae7174c5f07"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Sema 1.0 mg",
              "nAtRisk": 404,
              "ratePct": 11.4,
              "rowId": "fdd856ab-9274-4a9a-83f9-f94764593989"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 301,
              "ratePct": 14.3,
              "rowId": "587ff343-a818-4816-b49c-2c59e76663af"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 300,
              "ratePct": 13.7,
              "rowId": "70542385-9396-4a3b-b236-a503568a2af5"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 289,
              "ratePct": 15.6,
              "rowId": "3b5640bc-ab30-47fd-9b8b-7f1c31afe317"
            }
          ]
        },
        {
          "nct": "NCT03548935",
          "url": "https://clinicaltrials.gov/study/NCT03548935",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Sema 2.4 mg",
              "nAtRisk": 1306,
              "ratePct": 31.5,
              "rowId": "5d5db268-42a3-4db4-81b9-3e9f9e263fb3"
            }
          ]
        },
        {
          "nct": "NCT03552757",
          "url": "https://clinicaltrials.gov/study/NCT03552757",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 402,
              "ratePct": 21.9,
              "rowId": "71408f45-5963-4c70-b958-91aade698ac1"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 403,
              "ratePct": 21.3,
              "rowId": "ae0ff965-8d53-47b2-9c92-5a5c870df287"
            }
          ]
        },
        {
          "nct": "NCT03611582",
          "url": "https://clinicaltrials.gov/study/NCT03611582",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 407,
              "ratePct": 36.1,
              "rowId": "063e9c65-1d2d-4a9f-ad8b-5bbf5d837b63"
            }
          ]
        },
        {
          "nct": "NCT03811574",
          "url": "https://clinicaltrials.gov/study/NCT03811574",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.7 mg",
              "nAtRisk": 100,
              "ratePct": 22,
              "rowId": "ee2eb15b-3f2c-4268-a65f-bb2d5a541ff0"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 199,
              "ratePct": 16.1,
              "rowId": "669c4c54-4cd5-4d9a-9611-2b1f758d3b7e"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1 mg Semaglutide",
              "nAtRisk": 469,
              "ratePct": 11.5,
              "rowId": "0a621074-4b93-4e6d-868e-9849b7e6a901"
            }
          ]
        },
        {
          "nct": "NCT03989232",
          "url": "https://clinicaltrials.gov/study/NCT03989232",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 480,
              "ratePct": 8.8,
              "rowId": "e738bfb2-8849-47a8-bafa-cc8f4b79115e"
            },
            {
              "arm": "Semaglutide 2.0 mg",
              "nAtRisk": 479,
              "ratePct": 9.4,
              "rowId": "aa97617a-23d9-4d1d-8128-e1f74e6411eb"
            }
          ]
        },
        {
          "nct": "NCT04788511",
          "url": "https://clinicaltrials.gov/study/NCT04788511",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 263,
              "ratePct": 9.1,
              "rowId": "3d7aa9e7-1ef6-47ba-984a-9b521d375b44"
            }
          ]
        },
        {
          "nct": "NCT05064735",
          "url": "https://clinicaltrials.gov/study/NCT05064735",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 269,
              "ratePct": 7.8,
              "rowId": "e5e13f76-36c5-43f6-a471-0b9a67e0bfaa"
            }
          ]
        },
        {
          "nct": "NCT05646706",
          "url": "https://clinicaltrials.gov/study/NCT05646706",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 1004,
              "ratePct": 27.3,
              "rowId": "3fea0ac0-8e80-4e56-893a-74ed73668b03"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 201,
              "ratePct": 27.9,
              "rowId": "67a1ff3a-4618-4458-84be-5293be728b06"
            }
          ]
        },
        {
          "nct": "NCT05649137",
          "url": "https://clinicaltrials.gov/study/NCT05649137",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 307,
              "ratePct": 18.2,
              "rowId": "8469faa8-2266-44d7-b139-c6f7f461f491"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 103,
              "ratePct": 20.4,
              "rowId": "faac8480-63d8-46a8-83a6-ba2fd613691d"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "2.4 mg or MTD - Semaglutide",
              "nAtRisk": 376,
              "ratePct": 23.4,
              "rowId": "b706e87c-83ce-487f-80ee-6de55dff7e64"
            }
          ]
        }
      ]
    },
    {
      "effect": "diarrhea",
      "effectName": "Diarrhoea",
      "row": "tirzepatide",
      "rowLabel": "Tirzepatide",
      "drug": "tirzepatide",
      "status": "ok",
      "ratePct": 23.1,
      "ciLowPct": 14,
      "ciHighPct": 36,
      "statedRates": 27,
      "distinctTrials": 13,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 12,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 7,
        "obesity": 5,
        "cvot": 1
      },
      "dominantTrial": {
        "nct": "NCT04255433",
        "weightPct": 67.2
      },
      "obesityOnly": {
        "status": "ok",
        "ratePct": 23.1,
        "ciLowPct": 16,
        "ciHighPct": 33,
        "statedRates": 8,
        "distinctTrials": 5,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT03861039",
          "url": "https://clinicaltrials.gov/study/NCT03861039",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 7.4,
              "rowId": "35e3d4b9-6326-4cf9-9dd7-df771801b469"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 147,
              "ratePct": 13.6,
              "rowId": "c4e2aff4-4c63-4e12-9080-37387acb1103"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 13.5,
              "rowId": "a9d5c12d-d0a3-4d38-9ec1-2275d7556551"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 159,
              "ratePct": 17,
              "rowId": "d0989971-c7de-48c0-99a8-19f716f55d38"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 158,
              "ratePct": 8.9,
              "rowId": "1cd17fde-8b31-4ae7-b88a-a3a76a0cd88d"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 160,
              "ratePct": 11.3,
              "rowId": "71214a53-3bb0-4fbc-aa20-22aa8b427f83"
            }
          ]
        },
        {
          "nct": "NCT03954834",
          "url": "https://clinicaltrials.gov/study/NCT03954834",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 11.6,
              "rowId": "e4fa39c8-2a95-4f9a-ad1e-fe6f4ba5d913"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 14,
              "rowId": "551d0322-4f73-4173-93b8-f0196ab9896a"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 11.6,
              "rowId": "0db9cec5-c31d-4d49-bc58-0092b5d531d7"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 13.2,
              "rowId": "2b68c792-802c-411e-b29d-56b0c09378e9"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 469,
              "ratePct": 16.4,
              "rowId": "56915eae-5540-4cf2-8506-7c582c29ee53"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 13.8,
              "rowId": "c457e19a-5036-4bb0-b6b5-f4c98744f3fb"
            }
          ]
        },
        {
          "nct": "NCT04039503",
          "url": "https://clinicaltrials.gov/study/NCT04039503",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 116,
              "ratePct": 12.1,
              "rowId": "ba1d6f26-2d33-4798-a94f-7f1b5bdb64d6"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 119,
              "ratePct": 12.6,
              "rowId": "514bfb37-7604-4bbb-9c28-4628c1d09391"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 120,
              "ratePct": 20.8,
              "rowId": "32fb796b-1954-4318-b296-31e54ace4713"
            }
          ]
        },
        {
          "nct": "NCT04184622",
          "url": "https://clinicaltrials.gov/study/NCT04184622",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 20.3,
              "rowId": "4c3c4bcb-d4fd-41ce-884d-6a7c35b237f8"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 636,
              "ratePct": 22.5,
              "rowId": "324efc4e-e1e9-40ed-996c-d78e886e2b49"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 23.7,
              "rowId": "e8185edc-5587-4478-9213-2ad13c1b7e51"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Tirzepatide (MTD)",
              "nAtRisk": 6647,
              "ratePct": 24.7,
              "rowId": "3c9b154f-d568-46ae-a228-ce8e9361ad6d"
            }
          ]
        },
        {
          "nct": "NCT04657003",
          "url": "https://clinicaltrials.gov/study/NCT04657003",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 312,
              "ratePct": 19.9,
              "rowId": "41da1ab2-f63d-4a8f-9a6b-99a85a34aa29"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 311,
              "ratePct": 21.2,
              "rowId": "f2b8133e-e3bc-4626-a7e0-dbdfce2f9189"
            }
          ]
        },
        {
          "nct": "NCT04657016",
          "url": "https://clinicaltrials.gov/study/NCT04657016",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide",
              "nAtRisk": 287,
              "ratePct": 31,
              "rowId": "e4ca599e-2918-4d6b-8aaf-f862d559f92d"
            }
          ]
        },
        {
          "nct": "NCT04847557",
          "url": "https://clinicaltrials.gov/study/NCT04847557",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide - MTD",
              "nAtRisk": 364,
              "ratePct": 17.9,
              "rowId": "66483663-8619-48f9-b105-61563f330c80"
            }
          ]
        },
        {
          "nct": "NCT05412004",
          "url": "https://clinicaltrials.gov/study/NCT05412004",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide MTD_GPI1",
              "nAtRisk": 114,
              "ratePct": 26.3,
              "rowId": "9decfdfb-4342-4262-b519-e9eb24f3bbdb"
            },
            {
              "arm": "Tirzepatide MTD_GPI2",
              "nAtRisk": 119,
              "ratePct": 21.8,
              "rowId": "6c956efe-6a46-4600-8c6e-4e95a44b091a"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "15 mg Tirzepatide or MTD",
              "nAtRisk": 139,
              "ratePct": 22.3,
              "rowId": "b3e94f5a-a5ce-46d8-b4a0-3394e171f51d"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "15 mg or MTD - Tirzepatide",
              "nAtRisk": 374,
              "ratePct": 23.5,
              "rowId": "54b2e954-52b2-4b71-be86-158ea2648618"
            }
          ]
        }
      ]
    },
    {
      "effect": "diarrhea",
      "effectName": "Diarrhoea",
      "row": "liraglutide",
      "rowLabel": "Liraglutide",
      "drug": "liraglutide",
      "status": "ok",
      "ratePct": 11.2,
      "ciLowPct": 4,
      "ciHighPct": 26,
      "statedRates": 19,
      "distinctTrials": 13,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 12,
        "PHASE4": 1
      },
      "indicationMix": {
        "obesity": 3,
        "t2d": 7,
        "cvot": 1,
        "t1d_adjunct": 2
      },
      "dominantTrial": {
        "nct": "NCT01179048",
        "weightPct": 50.3
      },
      "obesityOnly": {
        "status": "ok",
        "ratePct": 22.4,
        "ciLowPct": 18,
        "ciHighPct": 28,
        "statedRates": 5,
        "distinctTrials": 3,
        "dominantTrial": {
          "nct": "NCT01272219",
          "weightPct": 70.6
        }
      },
      "trials": [
        {
          "nct": "NCT00781937",
          "url": "https://clinicaltrials.gov/study/NCT00781937",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Lira 3.0 mg",
              "nAtRisk": 212,
              "ratePct": 17.9,
              "rowId": "e3c36254-31e6-47a6-a0e2-972850959cf4"
            }
          ]
        },
        {
          "nct": "NCT01029886",
          "url": "https://clinicaltrials.gov/study/NCT01029886",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide Once Daily",
              "nAtRisk": 450,
              "ratePct": 12.9,
              "rowId": "5569d620-7b25-4c3c-ad02-d007b2d453aa"
            }
          ]
        },
        {
          "nct": "NCT01179048",
          "url": "https://clinicaltrials.gov/study/NCT01179048",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 4668,
              "ratePct": 5.7,
              "rowId": "4392ab66-9c95-4653-8db0-296fb21fad8b"
            }
          ]
        },
        {
          "nct": "NCT01272219",
          "url": "https://clinicaltrials.gov/study/NCT01272219",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg, Pre-diabetes",
              "nAtRisk": 1524,
              "ratePct": 25.5,
              "rowId": "3893078a-079e-4ea3-88cb-871f1cc948b5"
            },
            {
              "arm": "Liraglutide 3.0 mg, no Pre-diabetes",
              "nAtRisk": 957,
              "ratePct": 21,
              "rowId": "791b4561-1920-4e16-a278-b589e675e635"
            }
          ]
        },
        {
          "nct": "NCT01272232",
          "url": "https://clinicaltrials.gov/study/NCT01272232",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg",
              "nAtRisk": 422,
              "ratePct": 25.6,
              "rowId": "698e67fb-6b02-45de-9fd3-d160f57b4ec1"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 210,
              "ratePct": 17.6,
              "rowId": "b6db7a32-965b-45b7-8f09-fcdb22519cd5"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 137,
              "ratePct": 4.4,
              "rowId": "61b29b80-9938-4952-a663-534b10da82ed"
            }
          ]
        },
        {
          "nct": "NCT01617434",
          "url": "https://clinicaltrials.gov/study/NCT01617434",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 225,
              "ratePct": 10.7,
              "rowId": "11445865-8d97-4400-8111-9fd453b0a510"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.8 mg Liraglutide",
              "nAtRisk": 300,
              "ratePct": 12,
              "rowId": "205842ce-f37c-4b2c-8e0f-476c4bf59770"
            }
          ]
        },
        {
          "nct": "NCT01836523",
          "url": "https://clinicaltrials.gov/study/NCT01836523",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 350,
              "ratePct": 11.7,
              "rowId": "e8c4707a-8258-4d34-a56e-1769a799e74c"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 348,
              "ratePct": 14.4,
              "rowId": "561eb693-3407-47aa-be38-befb10308ee8"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 347,
              "ratePct": 18.4,
              "rowId": "cffc5422-d894-473a-a37e-1e09df265140"
            }
          ]
        },
        {
          "nct": "NCT01973231",
          "url": "https://clinicaltrials.gov/study/NCT01973231",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 202,
              "ratePct": 12.4,
              "rowId": "08ebb169-3dc6-4f0b-af8b-ea4137a2727f"
            }
          ]
        },
        {
          "nct": "NCT02098395",
          "url": "https://clinicaltrials.gov/study/NCT02098395",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 211,
              "ratePct": 6.6,
              "rowId": "936c3b1b-ccc7-4269-9897-94468f0fee5d"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 209,
              "ratePct": 12,
              "rowId": "82fe17d6-d0e2-4d98-8784-2a166669d20d"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 206,
              "ratePct": 14.6,
              "rowId": "9d626384-8abf-43ab-a64f-c7cc3fd6c963"
            }
          ]
        },
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 284,
              "ratePct": 10.9,
              "rowId": "e7b40336-074c-4c96-9cb8-496ab58a8a86"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 287,
              "ratePct": 12.2,
              "rowId": "61e0b507-a4ef-4d0c-9829-492d14b5f28d"
            }
          ]
        }
      ]
    },
    {
      "effect": "diarrhea",
      "effectName": "Diarrhoea",
      "row": "dulaglutide",
      "rowLabel": "Dulaglutide",
      "drug": "dulaglutide",
      "status": "ok",
      "ratePct": 15.5,
      "ciLowPct": 10,
      "ciHighPct": 24,
      "statedRates": 16,
      "distinctTrials": 11,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 10,
        "PHASE4": 1
      },
      "indicationMix": {
        "cvot": 2,
        "t2d": 9
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01394952",
          "url": "https://clinicaltrials.gov/study/NCT01394952",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Dulaglutide",
              "nAtRisk": 4943,
              "ratePct": 13.5,
              "rowId": "b3e0e136-d29f-4da5-b3c3-f4843c435c9f"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "LY2189265",
              "nAtRisk": 280,
              "ratePct": 7.1,
              "rowId": "a4b7da0d-152d-45f5-a0d2-4dc8fca1d66f"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.5 mg LY2189265",
              "nAtRisk": 299,
              "ratePct": 12,
              "rowId": "306c1e30-dde0-4165-845f-105b170e8e8f"
            }
          ]
        },
        {
          "nct": "NCT02597049",
          "url": "https://clinicaltrials.gov/study/NCT02597049",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.5 mg Dulaglutide",
              "nAtRisk": 142,
              "ratePct": 5.6,
              "rowId": "ff821087-095e-47eb-9d25-5031944ac0e9"
            },
            {
              "arm": "0.75 mg Dulaglutide",
              "nAtRisk": 141,
              "ratePct": 9.9,
              "rowId": "3e3b8ae8-77aa-435a-bd5a-5f806619bd97"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 299,
              "ratePct": 7.7,
              "rowId": "10baa48e-f4e3-4616-a56f-cf08f01d4401"
            },
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 299,
              "ratePct": 17.7,
              "rowId": "3a381672-f9a6-4d3f-be82-569f8f33646b"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 65,
              "ratePct": 6.2,
              "rowId": "942e08c2-fafb-4758-903a-a83dafc0dbfc"
            }
          ]
        },
        {
          "nct": "NCT03495102",
          "url": "https://clinicaltrials.gov/study/NCT03495102",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 612,
              "ratePct": 7.8,
              "rowId": "f5540961-507c-49d8-a1f1-9fb5a0842451"
            },
            {
              "arm": "Dulaglutide 3 mg",
              "nAtRisk": 616,
              "ratePct": 12.2,
              "rowId": "566d6c4f-6d5f-4597-ad64-e90330fb45e3"
            },
            {
              "arm": "Dulaglutide 4.5 mg",
              "nAtRisk": 614,
              "ratePct": 11.4,
              "rowId": "587200f1-a685-4b07-8086-086d7d3d17a4"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "0.75 mg Dulaglutide",
              "nAtRisk": 159,
              "ratePct": 6.9,
              "rowId": "abe9135a-9eae-4db9-8bba-f30be2eee12c"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "1.5 mg Dulaglutide",
              "nAtRisk": 6647,
              "ratePct": 18.9,
              "rowId": "0e236a84-30a1-4352-949b-9a58108c2c83"
            }
          ]
        },
        {
          "nct": "NCT04809220",
          "url": "https://clinicaltrials.gov/study/NCT04809220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 391,
              "ratePct": 10.2,
              "rowId": "78a8f6e9-fdd2-4de0-b4b6-c7d71bf4b30c"
            },
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 195,
              "ratePct": 8.2,
              "rowId": "dfc9e30f-8f25-42ee-ba4e-600648df23c3"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "4.5 mg Dulaglutide or MTD",
              "nAtRisk": 143,
              "ratePct": 13.3,
              "rowId": "33b21da7-e022-443f-b970-8d4034c98660"
            }
          ]
        }
      ]
    },
    {
      "effect": "diarrhea",
      "effectName": "Diarrhoea",
      "row": "exenatide",
      "rowLabel": "Exenatide",
      "drug": "exenatide",
      "status": "ok",
      "ratePct": 9.6,
      "ciLowPct": 4,
      "ciHighPct": 23,
      "statedRates": 5,
      "distinctTrials": 4,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 4
      },
      "indicationMix": {
        "t2d": 4
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide",
              "nAtRisk": 316,
              "ratePct": 17.1,
              "rowId": "fc49d0f2-299f-4603-a0b6-cd5e6d6da6c2"
            }
          ]
        },
        {
          "nct": "NCT00917267",
          "url": "https://clinicaltrials.gov/study/NCT00917267",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide Once Weekly",
              "nAtRisk": 340,
              "ratePct": 9.4,
              "rowId": "4d092943-5d86-45ec-8cea-9563acacc727"
            },
            {
              "arm": "Exenatide Twice Daily",
              "nAtRisk": 338,
              "ratePct": 8,
              "rowId": "9664b5db-8e08-436e-ba2f-74f7de3bd366"
            }
          ]
        },
        {
          "nct": "NCT01029886",
          "url": "https://clinicaltrials.gov/study/NCT01029886",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide Once Weekly",
              "nAtRisk": 461,
              "ratePct": 6.1,
              "rowId": "2967d054-0f89-4727-9a25-5441e2b5bb29"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide ER",
              "nAtRisk": 405,
              "ratePct": 8.4,
              "rowId": "ff0a01ae-c46d-4e6d-8638-5a5ad442595b"
            }
          ]
        }
      ]
    },
    {
      "effect": "diarrhea",
      "effectName": "Diarrhoea",
      "row": "lixisenatide",
      "rowLabel": "Lixisenatide",
      "drug": "lixisenatide",
      "status": "ok",
      "ratePct": 9.3,
      "ciLowPct": 5,
      "ciHighPct": 16,
      "statedRates": 7,
      "distinctTrials": 7,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 6,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 6,
        "cvot": 1
      },
      "dominantTrial": {
        "nct": "NCT01147250",
        "weightPct": 60.6
      },
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 318,
              "ratePct": 15.1,
              "rowId": "d0eb77cf-e9d1-440d-890e-b0fa9218d3c6"
            }
          ]
        },
        {
          "nct": "NCT00713830",
          "url": "https://clinicaltrials.gov/study/NCT00713830",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 574,
              "ratePct": 12.4,
              "rowId": "9441260b-596a-4fd4-87fd-866a2377249a"
            }
          ]
        },
        {
          "nct": "NCT00715624",
          "url": "https://clinicaltrials.gov/study/NCT00715624",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 328,
              "ratePct": 11.3,
              "rowId": "1cd76122-3677-4860-8120-b88bfb033fb2"
            }
          ]
        },
        {
          "nct": "NCT00763815",
          "url": "https://clinicaltrials.gov/study/NCT00763815",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 323,
              "ratePct": 10.8,
              "rowId": "1afb4177-ecbb-4814-9c7e-7c8b535b3ec1"
            }
          ]
        },
        {
          "nct": "NCT00975286",
          "url": "https://clinicaltrials.gov/study/NCT00975286",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 223,
              "ratePct": 6.7,
              "rowId": "85cff373-d492-4a8c-9dc1-1f4605919ea7"
            }
          ]
        },
        {
          "nct": "NCT01147250",
          "url": "https://clinicaltrials.gov/study/NCT01147250",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 3031,
              "ratePct": 7.8,
              "rowId": "eeea12af-1bdc-48cd-92fc-c5f2eeacd9a2"
            }
          ]
        },
        {
          "nct": "NCT01973231",
          "url": "https://clinicaltrials.gov/study/NCT01973231",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 202,
              "ratePct": 9.9,
              "rowId": "93228b06-e79d-42cc-b8c1-e0f562dfe186"
            }
          ]
        }
      ]
    },
    {
      "effect": "constipation",
      "effectName": "Constipation",
      "row": "semaglutide_oral",
      "rowLabel": "Semaglutide (oral)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 11.3,
      "ciLowPct": 3,
      "ciHighPct": 39,
      "statedRates": 17,
      "distinctTrials": 8,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 8
      },
      "indicationMix": {
        "t2d": 6,
        "obesity": 2
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 2,
        "distinctTrials": 2,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 285,
              "ratePct": 7.7,
              "rowId": "97df6f78-af57-4953-a750-938d5c56db67"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 131,
              "ratePct": 9.2,
              "rowId": "4acaa9ba-7159-43d0-9ee9-627552071e11"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 132,
              "ratePct": 12.1,
              "rowId": "5b4ee77c-180f-42f2-8532-c1ff78f69ac1"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 130,
              "ratePct": 15.4,
              "rowId": "32e88d85-9524-4ebb-9a0a-b1a6b7d2b204"
            }
          ]
        },
        {
          "nct": "NCT03021187",
          "url": "https://clinicaltrials.gov/study/NCT03021187",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 184,
              "ratePct": 4.3,
              "rowId": "7f041729-b957-4f06-b5a3-d1959c53f842"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 181,
              "ratePct": 8.3,
              "rowId": "6bb02b3a-67cc-4282-877d-ae976a3e01e4"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 181,
              "ratePct": 6.6,
              "rowId": "2b2e2de5-03b6-4a9d-b2f3-16608ea02f20"
            }
          ]
        },
        {
          "nct": "NCT04109547",
          "url": "https://clinicaltrials.gov/study/NCT04109547",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 3 mg",
              "nAtRisk": 130,
              "ratePct": 0.8,
              "rowId": "3c8143c9-1198-48cb-8fe7-091a6b0709c4"
            },
            {
              "arm": "Oral Semaglutide 7 mg",
              "nAtRisk": 130,
              "ratePct": 5.4,
              "rowId": "1112e7f3-040c-4c66-8f0d-13e49eda3c1f"
            },
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 129,
              "ratePct": 2.3,
              "rowId": "aa754aa0-2e49-4d2e-88c3-cf1372b0ed24"
            }
          ]
        },
        {
          "nct": "NCT04707469",
          "url": "https://clinicaltrials.gov/study/NCT04707469",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Oral Semaglutide 14 mg",
              "nAtRisk": 534,
              "ratePct": 7.5,
              "rowId": "1216ae96-871c-4b1b-bc9a-1c77d34172cf"
            },
            {
              "arm": "Oral Semaglutide 25 mg",
              "nAtRisk": 534,
              "ratePct": 6.6,
              "rowId": "b3605c07-c8de-4695-8c2a-826c37153c98"
            },
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 534,
              "ratePct": 6.2,
              "rowId": "f39a7c28-563e-4cf1-8641-65d1932096d2"
            }
          ]
        },
        {
          "nct": "NCT05035095",
          "url": "https://clinicaltrials.gov/study/NCT05035095",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 334,
              "ratePct": 27.5,
              "rowId": "15991c03-33af-4a33-985b-f81067742f71"
            }
          ]
        },
        {
          "nct": "NCT05132088",
          "url": "https://clinicaltrials.gov/study/NCT05132088",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Oral Semaglutide 50 mg",
              "nAtRisk": 134,
              "ratePct": 20.9,
              "rowId": "ca6adeb5-5ad9-4ad0-b7ac-b9227130c533"
            }
          ]
        },
        {
          "nct": "NCT06045221",
          "url": "https://clinicaltrials.gov/study/NCT06045221",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "7 mg Semaglutide",
              "nAtRisk": 426,
              "ratePct": 7.7,
              "rowId": "2c6639b9-a94b-41b8-8f28-74ddb3cdfa95"
            },
            {
              "arm": "14 mg Semaglutide",
              "nAtRisk": 425,
              "ratePct": 8.9,
              "rowId": "ae344e92-09d5-4c96-a732-4dd9dd2c49e4"
            }
          ]
        }
      ]
    },
    {
      "effect": "constipation",
      "effectName": "Constipation",
      "row": "semaglutide_injectable",
      "rowLabel": "Semaglutide (injectable)",
      "drug": "semaglutide",
      "status": "ok",
      "ratePct": 16.6,
      "ciLowPct": 5,
      "ciHighPct": 45,
      "statedRates": 20,
      "distinctTrials": 14,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 14
      },
      "indicationMix": {
        "cvot": 1,
        "t2d": 5,
        "obesity": 8
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "ok",
        "ratePct": 22,
        "ciLowPct": 9,
        "ciHighPct": 45,
        "statedRates": 11,
        "distinctTrials": 8,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01720446",
          "url": "https://clinicaltrials.gov/study/NCT01720446",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 826,
              "ratePct": 5.6,
              "rowId": "5e5d0437-0d86-485d-a260-6b0973508ec3"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 822,
              "ratePct": 9.6,
              "rowId": "39adefe5-e7bf-4504-aa09-edad0363762d"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Sema 1.0 mg",
              "nAtRisk": 404,
              "ratePct": 6.4,
              "rowId": "2aacfa32-d280-41c9-9a96-87353877c162"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 0.5 mg",
              "nAtRisk": 301,
              "ratePct": 5.3,
              "rowId": "b8e631cd-dff6-4359-9188-821cacd51fb8"
            },
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 300,
              "ratePct": 4.7,
              "rowId": "2352b4bd-6370-4ed1-93c2-f4738cd09dcb"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 289,
              "ratePct": 5.9,
              "rowId": "089e1dd0-2cbd-4820-9639-73b1bab45f4f"
            }
          ]
        },
        {
          "nct": "NCT03548935",
          "url": "https://clinicaltrials.gov/study/NCT03548935",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Sema 2.4 mg",
              "nAtRisk": 1306,
              "ratePct": 23.4,
              "rowId": "5bbfb657-f0fa-4543-8458-c171b368bb83"
            }
          ]
        },
        {
          "nct": "NCT03552757",
          "url": "https://clinicaltrials.gov/study/NCT03552757",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.0 mg",
              "nAtRisk": 402,
              "ratePct": 12.7,
              "rowId": "b2517f7d-62f2-4e25-aa7b-abc111f2d2a1"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 403,
              "ratePct": 17.4,
              "rowId": "4901d59d-5b96-4d01-a9af-f2ed30bc7aed"
            }
          ]
        },
        {
          "nct": "NCT03611582",
          "url": "https://clinicaltrials.gov/study/NCT03611582",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 407,
              "ratePct": 36.9,
              "rowId": "e708e0d8-8dfd-42a9-9a2c-5f11f3a70283"
            }
          ]
        },
        {
          "nct": "NCT03811574",
          "url": "https://clinicaltrials.gov/study/NCT03811574",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 1.7 mg",
              "nAtRisk": 100,
              "ratePct": 19,
              "rowId": "300d3a94-386e-4286-bc25-1623fb15bcdf"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 199,
              "ratePct": 26.1,
              "rowId": "2c4204ed-6c14-47a5-ae69-84c8422c8896"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1 mg Semaglutide",
              "nAtRisk": 469,
              "ratePct": 5.8,
              "rowId": "1f8ce591-2add-4cba-897a-df5703c8b9bb"
            }
          ]
        },
        {
          "nct": "NCT04788511",
          "url": "https://clinicaltrials.gov/study/NCT04788511",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 263,
              "ratePct": 6.5,
              "rowId": "af2d16dd-383f-41dd-98d1-42fcbfb6bd1c"
            }
          ]
        },
        {
          "nct": "NCT05064735",
          "url": "https://clinicaltrials.gov/study/NCT05064735",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 269,
              "ratePct": 11.9,
              "rowId": "1d6518b1-5a06-4000-8230-236712f34204"
            }
          ]
        },
        {
          "nct": "NCT05646706",
          "url": "https://clinicaltrials.gov/study/NCT05646706",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 1004,
              "ratePct": 23.3,
              "rowId": "db0723e3-0488-4f2d-adb3-687f81b3a667"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 201,
              "ratePct": 19.4,
              "rowId": "ff2d991d-946e-48ce-b85b-1da25460124d"
            }
          ]
        },
        {
          "nct": "NCT05649137",
          "url": "https://clinicaltrials.gov/study/NCT05649137",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Semaglutide 7.2 mg",
              "nAtRisk": 307,
              "ratePct": 14.7,
              "rowId": "314d6cba-64fe-4bbc-8b0f-04997e9a40b9"
            },
            {
              "arm": "Semaglutide 2.4 mg",
              "nAtRisk": 103,
              "ratePct": 18.4,
              "rowId": "16906ba7-31d0-4d72-8c77-31373e97318c"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "2.4 mg or MTD - Semaglutide",
              "nAtRisk": 376,
              "ratePct": 28.5,
              "rowId": "d0efb256-bc10-41ba-9a58-4fe456710146"
            }
          ]
        }
      ]
    },
    {
      "effect": "constipation",
      "effectName": "Constipation",
      "row": "tirzepatide",
      "rowLabel": "Tirzepatide",
      "drug": "tirzepatide",
      "status": "ok",
      "ratePct": 13.1,
      "ciLowPct": 5,
      "ciHighPct": 31,
      "statedRates": 27,
      "distinctTrials": 13,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 12,
        "PHASE4": 1
      },
      "indicationMix": {
        "t2d": 7,
        "obesity": 5,
        "cvot": 1
      },
      "dominantTrial": {
        "nct": "NCT04255433",
        "weightPct": 67.2
      },
      "obesityOnly": {
        "status": "ok",
        "ratePct": 19.3,
        "ciLowPct": 11,
        "ciHighPct": 31,
        "statedRates": 8,
        "distinctTrials": 5,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT03861039",
          "url": "https://clinicaltrials.gov/study/NCT03861039",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 8.1,
              "rowId": "a9579bee-c2f5-43ff-8647-72a343c3a6eb"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 147,
              "ratePct": 13.6,
              "rowId": "cbdfe583-a9b3-44db-8d9f-2118f42e1a51"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 148,
              "ratePct": 14.9,
              "rowId": "db7d0574-3ad1-4d40-84e0-24d7f4151bf3"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 159,
              "ratePct": 15.1,
              "rowId": "1c385f1a-c7ee-40cc-8ccc-826bef716b47"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 158,
              "ratePct": 17.7,
              "rowId": "0316312a-6cd8-4b52-b256-03899c00ec0b"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 160,
              "ratePct": 13.8,
              "rowId": "f1c7e1fe-8152-4c79-b233-38f8a2faa335"
            }
          ]
        },
        {
          "nct": "NCT03954834",
          "url": "https://clinicaltrials.gov/study/NCT03954834",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 5.8,
              "rowId": "b55c89fd-ab40-42b4-a733-49006be6ebe0"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 5,
              "rowId": "2cf31553-9789-4295-bccc-8e18aaf994ae"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 121,
              "ratePct": 6.6,
              "rowId": "0056061c-1729-414f-86ed-1d59198cf14f"
            }
          ]
        },
        {
          "nct": "NCT03987919",
          "url": "https://clinicaltrials.gov/study/NCT03987919",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 6.6,
              "rowId": "dbdae156-b5b6-4c89-a1d5-66a543315a57"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 469,
              "ratePct": 4.5,
              "rowId": "7dbf44af-ef57-4c01-ac10-1be2e76b2491"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 470,
              "ratePct": 4.5,
              "rowId": "f1d24d0d-d581-4a9d-9d86-f60d9b2bc049"
            }
          ]
        },
        {
          "nct": "NCT04039503",
          "url": "https://clinicaltrials.gov/study/NCT04039503",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 116,
              "ratePct": 6,
              "rowId": "99ff9da4-29d5-4f55-87c1-6c2d74ee2976"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 119,
              "ratePct": 6.7,
              "rowId": "9b9b5c83-f128-4de5-9a56-98866a02407c"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 120,
              "ratePct": 6.7,
              "rowId": "9e80d39c-5270-47a1-be28-ddd0a7c58ac5"
            }
          ]
        },
        {
          "nct": "NCT04184622",
          "url": "https://clinicaltrials.gov/study/NCT04184622",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "5 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 17.9,
              "rowId": "fb13fb14-cac3-4cc1-91db-e01ec27f1ed2"
            },
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 636,
              "ratePct": 18.4,
              "rowId": "41e30f9a-6535-4bc5-b3c1-afebf96b4905"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 630,
              "ratePct": 12.7,
              "rowId": "93da7bdf-935f-4c9a-9ab6-8b4d54fa0a77"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Tirzepatide (MTD)",
              "nAtRisk": 6647,
              "ratePct": 12.6,
              "rowId": "b6472a90-a0fa-4587-87de-79e3314ce0bb"
            }
          ]
        },
        {
          "nct": "NCT04657003",
          "url": "https://clinicaltrials.gov/study/NCT04657003",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "10 mg Tirzepatide",
              "nAtRisk": 312,
              "ratePct": 8,
              "rowId": "9ffca13a-eadb-45f8-9f07-fe45090dbd45"
            },
            {
              "arm": "15 mg Tirzepatide",
              "nAtRisk": 311,
              "ratePct": 9,
              "rowId": "b9357133-0859-4fe0-baa3-49cecc254e13"
            }
          ]
        },
        {
          "nct": "NCT04657016",
          "url": "https://clinicaltrials.gov/study/NCT04657016",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide",
              "nAtRisk": 287,
              "ratePct": 23,
              "rowId": "60d56bdb-f8b2-4c51-a89e-aaec90df900d"
            }
          ]
        },
        {
          "nct": "NCT04847557",
          "url": "https://clinicaltrials.gov/study/NCT04847557",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide - MTD",
              "nAtRisk": 364,
              "ratePct": 14.8,
              "rowId": "79bdd432-56cc-4b1a-bfb0-815259957660"
            }
          ]
        },
        {
          "nct": "NCT05412004",
          "url": "https://clinicaltrials.gov/study/NCT05412004",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Tirzepatide MTD_GPI1",
              "nAtRisk": 114,
              "ratePct": 15.8,
              "rowId": "2c731d4f-a09f-4e05-a143-69eddf736dcb"
            },
            {
              "arm": "Tirzepatide MTD_GPI2",
              "nAtRisk": 119,
              "ratePct": 15.1,
              "rowId": "7243ed64-55f9-433c-9df0-cf4af833f20b"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "15 mg Tirzepatide or MTD",
              "nAtRisk": 139,
              "ratePct": 8.6,
              "rowId": "910052a6-7a2a-4225-80f2-38abf99dbb71"
            }
          ]
        },
        {
          "nct": "NCT05822830",
          "url": "https://clinicaltrials.gov/study/NCT05822830",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "15 mg or MTD - Tirzepatide",
              "nAtRisk": 374,
              "ratePct": 27,
              "rowId": "9cf6231e-6e33-4139-b726-7e7053662cb5"
            }
          ]
        }
      ]
    },
    {
      "effect": "constipation",
      "effectName": "Constipation",
      "row": "liraglutide",
      "rowLabel": "Liraglutide",
      "drug": "liraglutide",
      "status": "ok",
      "ratePct": 13.6,
      "ciLowPct": 4,
      "ciHighPct": 37,
      "statedRates": 17,
      "distinctTrials": 10,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 10
      },
      "indicationMix": {
        "obesity": 3,
        "t2d": 5,
        "t1d_adjunct": 2
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "ok",
        "ratePct": 20.4,
        "ciLowPct": 10,
        "ciHighPct": 37,
        "statedRates": 5,
        "distinctTrials": 3,
        "dominantTrial": {
          "nct": "NCT01272219",
          "weightPct": 70.6
        }
      },
      "trials": [
        {
          "nct": "NCT00781937",
          "url": "https://clinicaltrials.gov/study/NCT00781937",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Lira 3.0 mg",
              "nAtRisk": 212,
              "ratePct": 26.9,
              "rowId": "e178266d-7383-4842-bb24-ba8dae09ae6b"
            }
          ]
        },
        {
          "nct": "NCT01272219",
          "url": "https://clinicaltrials.gov/study/NCT01272219",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg, Pre-diabetes",
              "nAtRisk": 1524,
              "ratePct": 21.9,
              "rowId": "9003cde6-2bcc-4315-8011-86ee60d29c6a"
            },
            {
              "arm": "Liraglutide 3.0 mg, no Pre-diabetes",
              "nAtRisk": 957,
              "ratePct": 21.2,
              "rowId": "c8d13ee3-aea7-4f77-8ad5-01b2b60e744c"
            }
          ]
        },
        {
          "nct": "NCT01272232",
          "url": "https://clinicaltrials.gov/study/NCT01272232",
          "phase": "PHASE3",
          "indication": "obesity",
          "arms": [
            {
              "arm": "Liraglutide 3.0 mg",
              "nAtRisk": 422,
              "ratePct": 16.1,
              "rowId": "c330d17c-5ca2-4491-8347-1d15c3e57e57"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 210,
              "ratePct": 9.5,
              "rowId": "e16a5e6a-d593-4a25-b9c4-2d8e5f66000b"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide",
              "nAtRisk": 137,
              "ratePct": 8,
              "rowId": "8e78e99a-c75f-4613-a3bc-d1aa31ce16b9"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.8 mg Liraglutide",
              "nAtRisk": 300,
              "ratePct": 5.7,
              "rowId": "f44c0765-7f76-44c5-94cc-f43fdd3f21a4"
            }
          ]
        },
        {
          "nct": "NCT01836523",
          "url": "https://clinicaltrials.gov/study/NCT01836523",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 350,
              "ratePct": 4.9,
              "rowId": "35b5dab7-ed0a-4977-a708-806ae1d00a7f"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 348,
              "ratePct": 8,
              "rowId": "dfdf2c46-17d7-4a05-a100-4740e196dc8d"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 347,
              "ratePct": 7.5,
              "rowId": "9240582a-c659-49ef-918e-d3baaab8f5b2"
            }
          ]
        },
        {
          "nct": "NCT02098395",
          "url": "https://clinicaltrials.gov/study/NCT02098395",
          "phase": "PHASE3",
          "indication": "t1d_adjunct",
          "arms": [
            {
              "arm": "Liraglutide 0.6 mg",
              "nAtRisk": 211,
              "ratePct": 2.8,
              "rowId": "50bfe4ce-c805-44ea-a5bc-39f589d2ada2"
            },
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 209,
              "ratePct": 11,
              "rowId": "c105a005-9410-48f8-b6a0-bbd8f570765a"
            },
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 206,
              "ratePct": 6.8,
              "rowId": "776c6c09-d562-4c3e-946e-f8a7e7ae9b9e"
            }
          ]
        },
        {
          "nct": "NCT02505334",
          "url": "https://clinicaltrials.gov/study/NCT02505334",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 233,
              "ratePct": 7.3,
              "rowId": "95a89a3a-e1cd-49ca-a9ea-0857a7f9320a"
            },
            {
              "arm": "Liraglutide 0.9 mg",
              "nAtRisk": 233,
              "ratePct": 2.1,
              "rowId": "968c45e2-a6e0-4832-adf6-fb420dd79b92"
            }
          ]
        },
        {
          "nct": "NCT02863419",
          "url": "https://clinicaltrials.gov/study/NCT02863419",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.8 mg",
              "nAtRisk": 284,
              "ratePct": 3.9,
              "rowId": "0ba2772e-3fae-4b68-bfd1-297b82b07285"
            }
          ]
        },
        {
          "nct": "NCT03191396",
          "url": "https://clinicaltrials.gov/study/NCT03191396",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Liraglutide 1.2 mg",
              "nAtRisk": 287,
              "ratePct": 3.5,
              "rowId": "3add9100-3d49-4038-862c-3e6e29db8164"
            }
          ]
        }
      ]
    },
    {
      "effect": "constipation",
      "effectName": "Constipation",
      "row": "dulaglutide",
      "rowLabel": "Dulaglutide",
      "drug": "dulaglutide",
      "status": "ok",
      "ratePct": 9.5,
      "ciLowPct": 5,
      "ciHighPct": 16,
      "statedRates": 11,
      "distinctTrials": 9,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 8,
        "PHASE4": 1
      },
      "indicationMix": {
        "cvot": 2,
        "t2d": 7
      },
      "dominantTrial": {
        "nct": "NCT04255433",
        "weightPct": 50.3
      },
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT01394952",
          "url": "https://clinicaltrials.gov/study/NCT01394952",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "Dulaglutide",
              "nAtRisk": 4943,
              "ratePct": 7.3,
              "rowId": "cbb567a8-ea12-4815-bde8-b54d60d8d68b"
            }
          ]
        },
        {
          "nct": "NCT01558271",
          "url": "https://clinicaltrials.gov/study/NCT01558271",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "LY2189265",
              "nAtRisk": 280,
              "ratePct": 7.9,
              "rowId": "bec10bf0-75ee-421d-a393-f84d10eef007"
            }
          ]
        },
        {
          "nct": "NCT01624259",
          "url": "https://clinicaltrials.gov/study/NCT01624259",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "1.5 mg LY2189265",
              "nAtRisk": 299,
              "ratePct": 3.7,
              "rowId": "c08ee87e-161d-4247-ae20-1ce0524b9155"
            }
          ]
        },
        {
          "nct": "NCT02648204",
          "url": "https://clinicaltrials.gov/study/NCT02648204",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 299,
              "ratePct": 3.3,
              "rowId": "3232c238-e06e-41c1-85cf-929b304018a6"
            },
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 299,
              "ratePct": 5,
              "rowId": "3cde4398-acdc-4072-9b40-c6f6a5213550"
            }
          ]
        },
        {
          "nct": "NCT03015220",
          "url": "https://clinicaltrials.gov/study/NCT03015220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 65,
              "ratePct": 9.2,
              "rowId": "1f487678-69a1-4ed3-8663-81251b5ebcf5"
            }
          ]
        },
        {
          "nct": "NCT03861052",
          "url": "https://clinicaltrials.gov/study/NCT03861052",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "0.75 mg Dulaglutide",
              "nAtRisk": 159,
              "ratePct": 10.7,
              "rowId": "a3d77a7b-e89d-4744-8497-c179fd500d6a"
            }
          ]
        },
        {
          "nct": "NCT04255433",
          "url": "https://clinicaltrials.gov/study/NCT04255433",
          "phase": "PHASE3",
          "indication": "cvot",
          "arms": [
            {
              "arm": "1.5 mg Dulaglutide",
              "nAtRisk": 6647,
              "ratePct": 11.6,
              "rowId": "c6c8e113-40a3-4387-b9b2-685ce1fe94c8"
            }
          ]
        },
        {
          "nct": "NCT04809220",
          "url": "https://clinicaltrials.gov/study/NCT04809220",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Dulaglutide 1.5 mg",
              "nAtRisk": 391,
              "ratePct": 12.5,
              "rowId": "20be0305-01cd-4d5b-a9a2-443e99cc1a84"
            },
            {
              "arm": "Dulaglutide 0.75 mg",
              "nAtRisk": 195,
              "ratePct": 8.7,
              "rowId": "2f558410-87b7-4701-9086-c851579fd131"
            }
          ]
        },
        {
          "nct": "NCT05564039",
          "url": "https://clinicaltrials.gov/study/NCT05564039",
          "phase": "PHASE4",
          "indication": "t2d",
          "arms": [
            {
              "arm": "4.5 mg Dulaglutide or MTD",
              "nAtRisk": 143,
              "ratePct": 7.7,
              "rowId": "4ec6ac6e-87d7-453f-806b-41efc49c070a"
            }
          ]
        }
      ]
    },
    {
      "effect": "constipation",
      "effectName": "Constipation",
      "row": "exenatide",
      "rowLabel": "Exenatide",
      "drug": "exenatide",
      "status": "ok",
      "ratePct": 5.7,
      "ciLowPct": 4,
      "ciHighPct": 7,
      "statedRates": 4,
      "distinctTrials": 3,
      "intervalBasis": "sampling_plus_between_study",
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 3
      },
      "indicationMix": {
        "t2d": 3
      },
      "dominantTrial": null,
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide",
              "nAtRisk": 316,
              "ratePct": 5.4,
              "rowId": "6fe0c5bd-72e3-4316-b067-74f37d769a8e"
            }
          ]
        },
        {
          "nct": "NCT00917267",
          "url": "https://clinicaltrials.gov/study/NCT00917267",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide Once Weekly",
              "nAtRisk": 340,
              "ratePct": 5.9,
              "rowId": "977dd96a-4bd1-41eb-a16d-e6dfc8fcecd4"
            },
            {
              "arm": "Exenatide Twice Daily",
              "nAtRisk": 338,
              "ratePct": 7.1,
              "rowId": "b7a837fb-de22-43f8-954b-91faa1818ee1"
            }
          ]
        },
        {
          "nct": "NCT01885208",
          "url": "https://clinicaltrials.gov/study/NCT01885208",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Exenatide ER",
              "nAtRisk": 405,
              "ratePct": 5.2,
              "rowId": "19d03ffe-101b-4d92-b0d4-26c3281c82a5"
            }
          ]
        }
      ]
    },
    {
      "effect": "constipation",
      "effectName": "Constipation",
      "row": "lixisenatide",
      "rowLabel": "Lixisenatide",
      "drug": "lixisenatide",
      "status": "insufficient_data",
      "ratePct": null,
      "ciLowPct": null,
      "ciHighPct": null,
      "statedRates": 2,
      "distinctTrials": 2,
      "intervalBasis": null,
      "seriousAeTrials": 0,
      "phaseMix": {
        "PHASE3": 2
      },
      "indicationMix": {
        "t2d": 2
      },
      "dominantTrial": {
        "nct": "NCT00713830",
        "weightPct": 64.3
      },
      "obesityOnly": {
        "status": "insufficient_data",
        "ratePct": null,
        "ciLowPct": null,
        "ciHighPct": null,
        "statedRates": 0,
        "distinctTrials": 0,
        "dominantTrial": null
      },
      "trials": [
        {
          "nct": "NCT00707031",
          "url": "https://clinicaltrials.gov/study/NCT00707031",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 318,
              "ratePct": 4.4,
              "rowId": "02692511-710c-456f-85b9-a0e87d6c1fea"
            }
          ]
        },
        {
          "nct": "NCT00713830",
          "url": "https://clinicaltrials.gov/study/NCT00713830",
          "phase": "PHASE3",
          "indication": "t2d",
          "arms": [
            {
              "arm": "Lixisenatide",
              "nAtRisk": 574,
              "ratePct": 5.2,
              "rowId": "8559600d-8b92-4b41-aec8-983ada53d77b"
            }
          ]
        }
      ]
    }
  ]
}